,doc_name,disease,species,mechanism_of_action,induction method,intervention,conclusive_statement,strain,viral strain,animal sex,
0,10079105.txt,Clostridium difficile,rat,neurotensin receptor antagonist,toxin A-induced,"SR-48,692",,,,,
1,10079105.txt,Clostridium difficile,rat,"inhibited by the substance P (neurokinin-1) receptor antagonist CP-96,345",toxin A-induced,"SR-48,692",,,,,
2,10952564.txt,Clostridium difficile,hamster,,antibiotic-induced,nitazoxanide,"During 
the treatment period, NTZ (>/=7.5 mg/100 gbw), like metronidazole and 
vancomycin, prevented outward manifestations of clindamycin-induced C. difficile 
intestinal disease.",,,,
3,10952564.txt,Clostridium difficile,hamster,,antibiotic-induced,metronidazole,"During 
the treatment period, NTZ (>/=7.5 mg/100 gbw), like metronidazole and 
vancomycin, prevented outward manifestations of clindamycin-induced C. difficile 
intestinal disease.",,,,
4,10952564.txt,Clostridium difficile,hamster,,antibiotic-induced,vancomycin,"During 
the treatment period, NTZ (>/=7.5 mg/100 gbw), like metronidazole and 
vancomycin, prevented outward manifestations of clindamycin-induced C. difficile 
intestinal disease.",,,,
5,11254479.txt,Clostridium difficile,rat,"downregulated toxin A-mediated increase of 
macrophage inflammatory protein-2",toxin A,dexamethasone,"Administration of 
the glucocorticoid analog dexamethasone inhibited toxin A-induced intestinal 
secretion and inflammation",,,,
6,11254650.txt,Clostridium difficile,mice,,,Saccharomyces boulardii,"The 
administration of C. difficile toxoid A by gavage to S. boulardii-fed BALB/c 
mice caused a 1.8-fold increase in total small intestinal immunoglobulin A 
levels (P = 0.003) and a 4.4-fold increase in specific intestinal anti-toxin A 
levels (P < 0.001).",BALB/c,,,
7,11451694.txt,C. difficile disease,hamsters,high-molecular-weight soluble anionic polymer,toxin A,GT160-246,"GT160-246 protected 80% of the 
hamsters from mortality caused by infection with C. difficile",,,,
8,11451694.txt,C. difficile disease,hamsters,high-molecular-weight soluble anionic polymer,toxin A,GT160-246,cholestyramine protected only 10% of animals,,,,
9,11451694.txt,C. difficile disease,hamsters,high-molecular-weight soluble anionic polymer,toxin A,GT160-246,"metronidazole initially protected 100% of the hamsters from 
mortality, but upon removal of treatment, 80% of the hamsters had relapses and 
died",,,,
10,11451694.txt,C. difficile disease,hamsters,high-molecular-weight soluble anionic polymer,toxin A,cholestyramine,"GT160-246 protected 80% of the 
hamsters from mortality caused by infection with C. difficile",,,,
11,11451694.txt,C. difficile disease,hamsters,high-molecular-weight soluble anionic polymer,toxin A,cholestyramine,cholestyramine protected only 10% of animals,,,,
12,11451694.txt,C. difficile disease,hamsters,high-molecular-weight soluble anionic polymer,toxin A,cholestyramine,"metronidazole initially protected 100% of the hamsters from 
mortality, but upon removal of treatment, 80% of the hamsters had relapses and 
died",,,,
13,11451694.txt,C. difficile disease,hamsters,high-molecular-weight soluble anionic polymer,toxin A,metronidazole,"GT160-246 protected 80% of the 
hamsters from mortality caused by infection with C. difficile",,,,
14,11451694.txt,C. difficile disease,hamsters,high-molecular-weight soluble anionic polymer,toxin A,metronidazole,cholestyramine protected only 10% of animals,,,,
15,11451694.txt,C. difficile disease,hamsters,high-molecular-weight soluble anionic polymer,toxin A,metronidazole,"metronidazole initially protected 100% of the hamsters from 
mortality, but upon removal of treatment, 80% of the hamsters had relapses and 
died",,,,
16,11875005.txt,"Clostridium 
difficile",mice,,ileal loops,Met-RANTES,"The 
RANTES antagonist Met-RANTES significantly (P < 0.01) reduced the toxin 
A-induced increases in ileal fluid accumulation and myeloperoxidase activity in 
wild-type mice.",wild-type,,,
17,12235074.txt,Clostridium difficile,mice,,,igmesine,"Oral JO 2871 and igmesine dose dependently 
inhibited toxigenic diarrhoea in all models.",,,,
18,12235074.txt,Clostridium difficile,mice,,,JO 2871,"Oral JO 2871 and igmesine dose dependently 
inhibited toxigenic diarrhoea in all models.",,,,
19,14616550.txt,Clostridium difficile,Rats,"tolerance was probably mediated by AF induced via action of 
cholera toxin on the enteric nervous and immune system",toxin A,induced by the cholera toxin (CT),"peroral CT-treatment induced tolerance to CDA in rat small 
intestine",,,,
20,1488767.txt,Clostridium difficile.,mice,,inoculated with these toxins,Saccharomyces boulardii,able to protect mice inoculated with these toxins,,,,
21,15388461.txt,"Clostridium 
difficile-associated diarrhea",hamsters,,clindamycin-induced,vancomycin,"rifalazil-treated animals showed 
absence of epithelial cell damage, significantly reduced congestion and edema, 
and less, but not statistically significantly less, neutrophil infiltration 
compared to those of vehicle-treated animals.",Golden Syrian,,,
22,15388461.txt,"Clostridium 
difficile-associated diarrhea",hamsters,,clindamycin-induced,vancomycin,"vancomycin-treated 
animals demonstrated severe epithelial cell damage and mildly reduced congestion 
and edema.",Golden Syrian,,,
23,15388461.txt,"Clostridium 
difficile-associated diarrhea",hamsters,,clindamycin-induced,vancomycin,"hamsters relapsed and tested C. difficile toxin positive 
(by enzyme-linked immunosorbent assay) 10 to 15 days after discontinuation of 
vancomycin treatment",Golden Syrian,,,
24,15388461.txt,"Clostridium 
difficile-associated diarrhea",hamsters,,clindamycin-induced,vancomycin,"None of the rifalazil-treated hamsters showed signs of 
disease or presence of toxins in their feces 30 days after discontinuation of 
treatment.",Golden Syrian,,,
25,15388461.txt,"Clostridium 
difficile-associated diarrhea",hamsters,,clindamycin-induced,rifalazil,"rifalazil-treated animals showed 
absence of epithelial cell damage, significantly reduced congestion and edema, 
and less, but not statistically significantly less, neutrophil infiltration 
compared to those of vehicle-treated animals.",Golden Syrian,,,
26,15388461.txt,"Clostridium 
difficile-associated diarrhea",hamsters,,clindamycin-induced,rifalazil,"vancomycin-treated 
animals demonstrated severe epithelial cell damage and mildly reduced congestion 
and edema.",Golden Syrian,,,
27,15388461.txt,"Clostridium 
difficile-associated diarrhea",hamsters,,clindamycin-induced,rifalazil,"hamsters relapsed and tested C. difficile toxin positive 
(by enzyme-linked immunosorbent assay) 10 to 15 days after discontinuation of 
vancomycin treatment",Golden Syrian,,,
28,15388461.txt,"Clostridium 
difficile-associated diarrhea",hamsters,,clindamycin-induced,rifalazil,"None of the rifalazil-treated hamsters showed signs of 
disease or presence of toxins in their feces 30 days after discontinuation of 
treatment.",Golden Syrian,,,
29,15767259.txt,Clostridium difficile,mice,,,SB203580,"In intact mice, blockage of p38 
MAPK inhibited toxin A-mediated induction of COX-2 in enterocytes as well as 
lamina propria cells, and significantly blocked the toxin A-induced ileal 
secretion of fluid and PGE2.",,,,
30,15899406.txt,Clostridium difficile,hamster,,,anti-surface layer protein (SLP) antibodies,"Post-challenge 
survival was significantly prolonged in the anti-SLP treated group compared with 
control groups (P=0.0281 and P=0.0283).",,,,
31,15942869.txt,Clostridium difficile,mice,,,S. cerevisiae 905,"Histopathological 
results of intestines showed that the yeast also presented a good protective 
effect against oral challenge with C. difficile in GN mice (p<0.05).",gnotobiotic,,,
32,15942869.txt,Clostridium difficile,mice,,,S. cerevisiae 905,"Histopathological 
results of intestines showed that the yeast also presented a good protective 
effect against oral challenge with C. difficile in GN mice (p<0.05).",conventional,,,
33,16143709.txt,Clostridium difficile infection,hamster,,clindamycin-induced,vancomycin,"Both ramoplanin and vancomycin were 
associated with rapid symptom resolution in the hamster model",,,,
34,16143709.txt,Clostridium difficile infection,hamster,,clindamycin-induced,vancomycin,"C. difficile spores 
were recovered significantly more often from the caecal contents of 
vancomycin-treated (n = 19/23) compared with ramoplanin-treated (n = 6/23) 
hamsters (P < 0.05).",,,,
35,16143709.txt,Clostridium difficile infection,hamster,,clindamycin-induced,ramoplanin,"Both ramoplanin and vancomycin were 
associated with rapid symptom resolution in the hamster model",,,,
36,16143709.txt,Clostridium difficile infection,hamster,,clindamycin-induced,ramoplanin,"C. difficile spores 
were recovered significantly more often from the caecal contents of 
vancomycin-treated (n = 19/23) compared with ramoplanin-treated (n = 6/23) 
hamsters (P < 0.05).",,,,
37,16344056.txt,Clostridium difficile,mice,,,SB203580,"intact mice, p38 blockade suppressed toxin A-mediated destruction of intestinal 
villi, p21(WAF1/CIP1) expression, and enterocyte apoptosis.",,,,
38,16622196.txt,Clostridium difficile,murine,,toxin A-induced,ATL 313,"ATL 313 treatment significantly (P < 0.05) reduced toxin 
A-induced secretion and edema, prevented mucosal disruption, and neutrophil 
infiltration as measured by myeloperoxidase activity.",,,,
39,16622196.txt,Clostridium difficile,murine,,ileal loops.,ATL 313,"ATL 313 treatment significantly (P < 0.05) reduced toxin 
A-induced secretion and edema, prevented mucosal disruption, and neutrophil 
infiltration as measured by myeloperoxidase activity.",,,,
40,16816386.txt,Clostridium difficile.,mouse,"S. boulardii inhibits C. difficile toxin 
A-associated enteritis by blocking the activation of Erk1/2 MAP kinases.",toxin A,Saccharomyces boulardii,"SbS pretreatment completely normalized 
toxin A mediated fluid secretion (p < 0.01), and histopathologic changes (p < 
0.01) and substantially inhibited toxin A-associated KC increases (p < 0.001).",,,,
41,16966409.txt,C. difficile disease,mouse,,toxin A,3H2,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
42,16966409.txt,C. difficile disease,hamster,,toxin A,3H2,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
43,16966409.txt,C. difficile disease,mouse,,toxin A,3H2,"systemic toxicity in the mouse could not be 
neutralized.",,,,
44,16966409.txt,C. difficile disease,hamster,,toxin A,3H2,"systemic toxicity in the mouse could not be 
neutralized.",,,,
45,16966409.txt,C. difficile disease,mouse,,toxin A,3H2,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
46,16966409.txt,C. difficile disease,hamster,,toxin A,3H2,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
47,16966409.txt,C. difficile disease,mouse,,toxin A,CDA1,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
48,16966409.txt,C. difficile disease,hamster,,toxin A,CDA1,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
49,16966409.txt,C. difficile disease,mouse,,toxin A,CDA1,"systemic toxicity in the mouse could not be 
neutralized.",,,,
50,16966409.txt,C. difficile disease,hamster,,toxin A,CDA1,"systemic toxicity in the mouse could not be 
neutralized.",,,,
51,16966409.txt,C. difficile disease,mouse,,toxin A,CDA1,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
52,16966409.txt,C. difficile disease,hamster,,toxin A,CDA1,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
53,16966409.txt,C. difficile disease,mouse,,toxin A,1B11,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
54,16966409.txt,C. difficile disease,hamster,,toxin A,1B11,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
55,16966409.txt,C. difficile disease,mouse,,toxin A,1B11,"systemic toxicity in the mouse could not be 
neutralized.",,,,
56,16966409.txt,C. difficile disease,hamster,,toxin A,1B11,"systemic toxicity in the mouse could not be 
neutralized.",,,,
57,16966409.txt,C. difficile disease,mouse,,toxin A,1B11,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
58,16966409.txt,C. difficile disease,hamster,,toxin A,1B11,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
59,16966409.txt,C. difficile disease,mouse,,toxin A,MDX-1388,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
60,16966409.txt,C. difficile disease,hamster,,toxin A,MDX-1388,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
61,16966409.txt,C. difficile disease,mouse,,toxin A,MDX-1388,"systemic toxicity in the mouse could not be 
neutralized.",,,,
62,16966409.txt,C. difficile disease,hamster,,toxin A,MDX-1388,"systemic toxicity in the mouse could not be 
neutralized.",,,,
63,16966409.txt,C. difficile disease,mouse,,toxin A,MDX-1388,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
64,16966409.txt,C. difficile disease,hamster,,toxin A,MDX-1388,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
65,16966409.txt,C. difficile disease,mouse,,toxin A,103-174,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
66,16966409.txt,C. difficile disease,hamster,,toxin A,103-174,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
67,16966409.txt,C. difficile disease,mouse,,toxin A,103-174,"systemic toxicity in the mouse could not be 
neutralized.",,,,
68,16966409.txt,C. difficile disease,hamster,,toxin A,103-174,"systemic toxicity in the mouse could not be 
neutralized.",,,,
69,16966409.txt,C. difficile disease,mouse,,toxin A,103-174,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
70,16966409.txt,C. difficile disease,hamster,,toxin A,103-174,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
71,16966409.txt,C. difficile disease,mouse,,toxin A,1G10,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
72,16966409.txt,C. difficile disease,hamster,,toxin A,1G10,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
73,16966409.txt,C. difficile disease,mouse,,toxin A,1G10,"systemic toxicity in the mouse could not be 
neutralized.",,,,
74,16966409.txt,C. difficile disease,hamster,,toxin A,1G10,"systemic toxicity in the mouse could not be 
neutralized.",,,,
75,16966409.txt,C. difficile disease,mouse,,toxin A,1G10,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
76,16966409.txt,C. difficile disease,hamster,,toxin A,1G10,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
77,16966409.txt,C. difficile disease,mouse,,toxin A,2A11,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
78,16966409.txt,C. difficile disease,hamster,,toxin A,2A11,"inhibit the enterotoxicity of toxin A in mouse 
intestinal loops and the in vivo toxicity in a systemic mouse model.",,,,
79,16966409.txt,C. difficile disease,mouse,,toxin A,2A11,"systemic toxicity in the mouse could not be 
neutralized.",,,,
80,16966409.txt,C. difficile disease,hamster,,toxin A,2A11,"systemic toxicity in the mouse could not be 
neutralized.",,,,
81,16966409.txt,C. difficile disease,mouse,,toxin A,2A11,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
82,16966409.txt,C. difficile disease,hamster,,toxin A,2A11,"Compared to 
controls, combination therapy reduced mortality from 100% to 45% (P<0.0001) in 
the primary disease hamster model and from 78% to 32% (P<0.0001) in the less 
stringent relapse model.",,,,
83,17206941.txt,Clostridium difficile-associated diarrhoea.,hamster,,toxin A,tolevamer,"tolevamer reduces disease severity and recurrence rates in the hamster model of 
C. difficile-associated diarrhoea",,,,
84,17206941.txt,Clostridium difficile-associated diarrhoea.,rat,,toxin A,tolevamer,"tolevamer reduces disease severity and recurrence rates in the hamster model of 
C. difficile-associated diarrhoea",,,,
85,17206941.txt,Clostridium difficile-associated diarrhoea.,hamster,,toxin A,tolevamer,"blocks the enterotoxic effects of toxin A 
in rat ileum.",,,,
86,17206941.txt,Clostridium difficile-associated diarrhoea.,rat,,toxin A,tolevamer,"blocks the enterotoxic effects of toxin A 
in rat ileum.",,,,
87,1728517.txt,Clostridium difficile.,hamster,,clindamycin-treated hamster model.,yogurt,"Mortality was 100% in yogurt-treated animals, and all animals showed 
histological changes of severe colitis.",golden Syrian,,,
88,17570216.txt,Clostridium difficile,mice,,ileal loops,FUT-175,"In wild-type mice, FUT-175 or MPI-0442352 inhibited secretion by 24%-28% 
and tissue and fluid myeloperoxidase by 31%-71%.",wild-type,,,
89,17570216.txt,Clostridium difficile,mice,,ileal loops,FUT-175,"Soybean trypsin inhibitor 
reduced secretion to background levels and tissue myeloperoxidase by up to 50%.",wild-type,,,
90,17570216.txt,Clostridium difficile,mice,,ileal loops,MPI-0442352,"In wild-type mice, FUT-175 or MPI-0442352 inhibited secretion by 24%-28% 
and tissue and fluid myeloperoxidase by 31%-71%.",wild-type,,,
91,17570216.txt,Clostridium difficile,mice,,ileal loops,MPI-0442352,"Soybean trypsin inhibitor 
reduced secretion to background levels and tissue myeloperoxidase by up to 50%.",wild-type,,,
92,17570216.txt,Clostridium difficile,mice,,ileal loops,soybean trypsin inhibitor,"In wild-type mice, FUT-175 or MPI-0442352 inhibited secretion by 24%-28% 
and tissue and fluid myeloperoxidase by 31%-71%.",wild-type,,,
93,17570216.txt,Clostridium difficile,mice,,ileal loops,soybean trypsin inhibitor,"Soybean trypsin inhibitor 
reduced secretion to background levels and tissue myeloperoxidase by up to 50%.",wild-type,,,
94,17639289.txt,,mouse,p38 inhibitor,toxin A-induced,SB203580,"attenuated toxin A-induced inflammation in vivo in the mouse ileum, 
evidenced by a significant decrease in neutrophil infiltration, villous 
destruction, and mucosal congestion.",,,,
95,17805968.txt,"Clostridium 
difficile-associated diseases",mouse,"L-selectin 
blocker",toxin-A-induced,fucoidin,"fucoidin 
reduces tissue injury and inflammation in toxin-A-induced mouse enteritis.",,,,
96,18094539.txt,Clostridium difficile,mice,,,ampicillin,"The C. difficile 
count, toxin A and B titres and myeloperoxidase activity were significantly 
higher (P>0.05) in ampicillin and lansoprazole receiving groups as compared to 
the control and the C. difficile receiving groups.",BALB/c,,,
97,18094539.txt,Clostridium difficile,mice,,,lansoprazole,"The C. difficile 
count, toxin A and B titres and myeloperoxidase activity were significantly 
higher (P>0.05) in ampicillin and lansoprazole receiving groups as compared to 
the control and the C. difficile receiving groups.",BALB/c,,,
98,18195066.txt,C. difficile-associated diarrhea,hamster,,clindamycin,rifaximin,"There was no relapse after treatment with vancomycin or 
rifaximin in hamsters infected with the BI17 strain.",,,,
99,18195066.txt,C. difficile-associated diarrhea,hamster,,clindamycin,rifaximin,"Hamsters infected with the 
VPI 10463 strain and treated with rifaximin did not develop relapsing infection 
within a month of follow-up, whereas the majority of vancomycin-treated animals 
relapsed (0% versus 75%, respectively; P < 0.01).",,,,
100,18195066.txt,C. difficile-associated diarrhea,hamster,,clindamycin,Vancomycin,"There was no relapse after treatment with vancomycin or 
rifaximin in hamsters infected with the BI17 strain.",,,,
101,18195066.txt,C. difficile-associated diarrhea,hamster,,clindamycin,Vancomycin,"Hamsters infected with the 
VPI 10463 strain and treated with rifaximin did not develop relapsing infection 
within a month of follow-up, whereas the majority of vancomycin-treated animals 
relapsed (0% versus 75%, respectively; P < 0.01).",,,,
102,18693236.txt,"Clostridium 
difficile.",mice,,,ampicillin,"Administration of oral recombinant beta-lactamase preserved the 
colonic microbiota of mice during parenteral beta-lactam antibiotic treatment 
and prevented the overgrowth of and toxin production by C. difficile in caecal 
contents",,one of four strains of C. difficile,,
103,18693236.txt,"Clostridium 
difficile.",mice,,,piperacillin,"Administration of oral recombinant beta-lactamase preserved the 
colonic microbiota of mice during parenteral beta-lactam antibiotic treatment 
and prevented the overgrowth of and toxin production by C. difficile in caecal 
contents",,one of four strains of C. difficile,,
104,18693236.txt,"Clostridium 
difficile.",mice,,,beta-lactamase,"Administration of oral recombinant beta-lactamase preserved the 
colonic microbiota of mice during parenteral beta-lactam antibiotic treatment 
and prevented the overgrowth of and toxin production by C. difficile in caecal 
contents",,one of four strains of C. difficile,,
105,18693236.txt,"Clostridium 
difficile.",mice,,,"tazobactam-inactivated oral 
beta-lactamase","Administration of oral recombinant beta-lactamase preserved the 
colonic microbiota of mice during parenteral beta-lactam antibiotic treatment 
and prevented the overgrowth of and toxin production by C. difficile in caecal 
contents",,one of four strains of C. difficile,,
106,18848941.txt,Clostridium difficile,mice,,antibiotic-induced C. difficile-associated disease,vancomycin,"Oral vancomycin prevented CDAD in all mice, but 
68% died from colitis after treatment was discontinued.",C57BL/6,,,
107,1900059.txt,C. difficile disease,mice,,,monoclonal antibodies against toxin A,"In protected mice, toxin B levels were similar to those in dying 
mice, but toxin A levels were greatly reduced.",axenic,,,
108,1913342.txt,Clostridium difficile,mice,,,viable and nonviable Saccharomyces boulardii,"With 
the exception of irradiated S. boulardii, which retained some activity, only 
viable yeast protected the mice from lethality.",gnotobiotic,,,
109,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,112G6,"enterotoxicity, mouse lethality, 
haemagglutination activity and cytotoxicity, 37B5 neutralised enterotoxicity in 
a rabbit ileal loop response test but did not neutralise any other biological 
activities.",,,,
110,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,112G6,"None of the other eight mAbs showed any neutralising activities at 
all.",,,,
111,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,"2E15,","enterotoxicity, mouse lethality, 
haemagglutination activity and cytotoxicity, 37B5 neutralised enterotoxicity in 
a rabbit ileal loop response test but did not neutralise any other biological 
activities.",,,,
112,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,"2E15,","None of the other eight mAbs showed any neutralising activities at 
all.",,,,
113,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,"3B4,","enterotoxicity, mouse lethality, 
haemagglutination activity and cytotoxicity, 37B5 neutralised enterotoxicity in 
a rabbit ileal loop response test but did not neutralise any other biological 
activities.",,,,
114,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,"3B4,","None of the other eight mAbs showed any neutralising activities at 
all.",,,,
115,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,37B5,"enterotoxicity, mouse lethality, 
haemagglutination activity and cytotoxicity, 37B5 neutralised enterotoxicity in 
a rabbit ileal loop response test but did not neutralise any other biological 
activities.",,,,
116,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,37B5,"None of the other eight mAbs showed any neutralising activities at 
all.",,,,
117,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,49C4,"enterotoxicity, mouse lethality, 
haemagglutination activity and cytotoxicity, 37B5 neutralised enterotoxicity in 
a rabbit ileal loop response test but did not neutralise any other biological 
activities.",,,,
118,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,49C4,"None of the other eight mAbs showed any neutralising activities at 
all.",,,,
119,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,37B5,"enterotoxicity, mouse lethality, 
haemagglutination activity and cytotoxicity, 37B5 neutralised enterotoxicity in 
a rabbit ileal loop response test but did not neutralise any other biological 
activities.",,,,
120,1916231.txt,Clostridium difficile,rabbit,,ileal loop response test,37B5,"None of the other eight mAbs showed any neutralising activities at 
all.",,,,
121,19251726.txt,"Clostridium difficile 
infection",hamster,methionyl-tRNA synthetase inhibitor,clindamycin-induced,REP3123,"REP3123, at concentrations as low as 0.5 mg/kg, demonstrated efficacy in the 
hamster model of CDI and was superior to vancomycin in the overall survival of 
the animals at the end of the study (33 days).",,,,
122,1929250.txt,Clostridium difficile.,hamsters,,clindamycin-treated,Tiacumicins B and C,"Oral 
treatment with identical doses of vancomycin produced a prolonged, 
dose-dependent survival of hamsters, but it did not prevent the development of 
fatal colitis at doses of up to 5 mg/kg.",,,,
123,19416358.txt,Clostridium difficile,Mice,,intestinal loops,"yeast, beef and pork extracts","These results 
show that yeast, beef and pork extracts have the potential to counteract the 
intestinal pathogenesis triggered by C. difficile toxin A",,,,
124,19523775.txt,Clostridium difficile,dogs,,,"Bifidobacterium 
animalis AHC7","significantly reduced the carriage of Clostridia, in 
particular Clostridium difficile, in dogs",,,,
125,20074161.txt,"Clostridium 
difficile associated disease",mice,,cyclosporin daily from days 1-7 followed by C.,epidermal growth factor,Administration of biotherapeutics reduced the severity of CDAD.,BALB/c,,,
126,20074161.txt,"Clostridium 
difficile associated disease",mice,,cyclosporin daily from days 1-7 followed by C.,"Lactobacillus 
acidophilus",Administration of biotherapeutics reduced the severity of CDAD.,BALB/c,,,
127,20347817.txt,Clostridium difficile,Mice,,ileal loop model,HIF-1alpha,HIF-1alpha protects the intestinal mucosa from C difficile toxins.,"targeted deletion of HIF-1alpha in the intestinal 
epithelium",,,
128,20398664.txt,Clostridium difficile-associated disease (CDAD),mice,,,anakinra,"In vivo, deletion of ASC significantly reduced 
toxin-induced inflammation and damage, an effect that was mimicked by 
pretreatment with the IL-1 receptor antagonist anakinra.",,,,
129,20696758.txt,Clostridium difficile,mouse,"inhibitor of 
the HDAC6 tubulin deacetylase",toxin A-induced mouse enteritis model,trichostatin A (TSA),"attenuated 
proinflammatory cytokine production, mucosal damage, and epithelial cell 
apoptosis",,,,
130,21115723.txt,"Clostridium 
difficile-associated disease",mice,inhibitor of adenosine deaminase,ileal loop,"EHNA 
[erythro-9-(2-hydroxy-3-nonyl)-adenine]","Adenosine deaminase 
inhibition, by EHNA, reduced tissue injury, neutrophil infiltration, and the 
levels of proinflammatory cytokines (TNF-α and IL-1β) as well as the expression 
of NOS2, NF-κB, and PTX3 in the ileum of mice injected with TxA.",C57BL6,,,
131,21115723.txt,"Clostridium 
difficile-associated disease",mice,inhibitor of adenosine deaminase,ileal loop,"EHNA 
[erythro-9-(2-hydroxy-3-nonyl)-adenine]","ATL313 had no 
additional effect on EHNA action.",C57BL6,,,
132,21115723.txt,"Clostridium 
difficile-associated disease",mice,inhibitor of adenosine deaminase,ileal loop,ATL313,"Adenosine deaminase 
inhibition, by EHNA, reduced tissue injury, neutrophil infiltration, and the 
levels of proinflammatory cytokines (TNF-α and IL-1β) as well as the expression 
of NOS2, NF-κB, and PTX3 in the ileum of mice injected with TxA.",C57BL6,,,
133,21115723.txt,"Clostridium 
difficile-associated disease",mice,inhibitor of adenosine deaminase,ileal loop,ATL313,"ATL313 had no 
additional effect on EHNA action.",C57BL6,,,
134,21131421.txt,Clostridium difficile,mice,,toxin A into the ileal loops,CX3CL1/fractalkine,"tin-protoporphyrin-IX, markedly increased fluid accumulation",wild-type,,,
135,21131421.txt,Clostridium difficile,mice,,toxin A into the ileal loops,CX3CL1/fractalkine,"CX3CL1/FKN could induce 
CX3CR1-expressing macrophages to express HO-1, thereby ameliorating toxin 
A-induced enteritis.",wild-type,,,
136,21131421.txt,Clostridium difficile,mice,,toxin A into the ileal loops,tin-protoporphyrin-IX,"tin-protoporphyrin-IX, markedly increased fluid accumulation",wild-type,,,
137,21131421.txt,Clostridium difficile,mice,,toxin A into the ileal loops,tin-protoporphyrin-IX,"CX3CL1/FKN could induce 
CX3CR1-expressing macrophages to express HO-1, thereby ameliorating toxin 
A-induced enteritis.",wild-type,,,
138,21245274.txt,Clostridium difficile,mice,Toll-like receptor 5 (TLR5) agonist,,Salmonella-derived flagellin,"We demonstrate that restoring 
intestinal innate immune tone by TLR stimulation in antibiotic-treated mice 
ameliorates intestinal inflammation and prevents death from C. difficile 
colitis",,,,
139,21314706.txt,Clostridium difficile,pigs,"lacticin 3147, a broad-spectrum 
bacteriocin",,"Lactococcus 
lactis DPC6520",activity was undetectable in faecal samples,,,,
140,21372182.txt,Clostridium difficile,mice,a specific HO-1 inhibitor,toxin A-induced,"zinc protoporphyrin 
IX (ZnPP IX)","Treatment of mice subjected to C. difficile toxin A (TcdA) with haemin or 
DMDC prevented oedema, mucosal disruption and neutrophil infiltration observed 
in histological analysis.",,,,
141,21372182.txt,Clostridium difficile,mice,a specific HO-1 inhibitor,toxin A-induced,"zinc protoporphyrin 
IX (ZnPP IX)","In contrast, the specific HO-1 inhibitor (ZnPP IX) 
exacerbated all these evaluated parameters.",,,,
142,21372182.txt,Clostridium difficile,mice,"a CO 
donor",toxin A-induced,"zinc protoporphyrin 
IX (ZnPP IX)","Treatment of mice subjected to C. difficile toxin A (TcdA) with haemin or 
DMDC prevented oedema, mucosal disruption and neutrophil infiltration observed 
in histological analysis.",,,,
143,21372182.txt,Clostridium difficile,mice,"a CO 
donor",toxin A-induced,"zinc protoporphyrin 
IX (ZnPP IX)","In contrast, the specific HO-1 inhibitor (ZnPP IX) 
exacerbated all these evaluated parameters.",,,,
144,21372182.txt,Clostridium difficile,mice,a specific HO-1 inhibitor,toxin A-induced,dimanganese decacarbonyl (DMDC),"Treatment of mice subjected to C. difficile toxin A (TcdA) with haemin or 
DMDC prevented oedema, mucosal disruption and neutrophil infiltration observed 
in histological analysis.",,,,
145,21372182.txt,Clostridium difficile,mice,a specific HO-1 inhibitor,toxin A-induced,dimanganese decacarbonyl (DMDC),"In contrast, the specific HO-1 inhibitor (ZnPP IX) 
exacerbated all these evaluated parameters.",,,,
146,21372182.txt,Clostridium difficile,mice,"a CO 
donor",toxin A-induced,dimanganese decacarbonyl (DMDC),"Treatment of mice subjected to C. difficile toxin A (TcdA) with haemin or 
DMDC prevented oedema, mucosal disruption and neutrophil infiltration observed 
in histological analysis.",,,,
147,21372182.txt,Clostridium difficile,mice,"a CO 
donor",toxin A-induced,dimanganese decacarbonyl (DMDC),"In contrast, the specific HO-1 inhibitor (ZnPP IX) 
exacerbated all these evaluated parameters.",,,,
148,21393125.txt,,Mice,,"intraperitoneally injected with 0.2 mL of filter-sterilized 
C. difficile culture supernatant (CDT preparation).",intravenous immunoglobulin (IVIg),"The maximum effects of IVIg (100% survival) were observed when the mice were 
treated with IVIg at the same time as injection of the CDT preparation.",,,,
149,21393140.txt,Clostridium difficile.,hamster,,,RBx 11760,"In 
the hamster infection model, treatment with RBx 11760 resulted in prolonged 
survival of animals as compared with vancomycin or metronidazole, which 
correlated well with the histopathology results.",,,,
150,21537099.txt,Clostridium difficile-associated disease (CDAD),mice,,,Lactobacillus acidophilus,"acidophilus and EGF reduced the severity of C. difficile infection in the 
experimental animals",BALB/c,,,
151,21537099.txt,Clostridium difficile-associated disease (CDAD),mice,,,epidermal growth factor,"acidophilus and EGF reduced the severity of C. difficile infection in the 
experimental animals",BALB/c,,,
152,21537099.txt,Clostridium difficile-associated disease (CDAD),mice,,,ampicillin,"acidophilus and EGF reduced the severity of C. difficile infection in the 
experimental animals",BALB/c,,,
153,21537099.txt,Clostridium difficile-associated disease (CDAD),mice,,,lansoprazole,"acidophilus and EGF reduced the severity of C. difficile infection in the 
experimental animals",BALB/c,,,
154,21576341.txt,Recurrent C. difficile infection,mouse,,relapse CDI model,vancomycin,"we demonstrated that 
vancomycin only delayed disease recurrence",,,,
155,21807975.txt,Clostridium difficile-associated diarrhea,mouse,,antibiotics followed by C. difficile infection.,"coprisin 
analogue","coprisin treatment significantly ameliorated body weight decreases, improved the 
survival rate, and decreased mucosal damage and proinflammatory cytokine 
production",,,,
156,21857653.txt,Clostridium difficile infection,mouse,,,InsP(6),"treatment with 
exogenous InsP(6) enhanced the therapeutic actions of oral S-nitrosothiols in 
mouse models of C. difficile infection.",,,,
157,2200843.txt,Clostridium difficile,mice,,,Saccharomyces boulardii,"The results showed that: (i) 70% of the mice infected by C. difficile 
survived when treated with S. boulardii; (ii) the C. difficile-induced lesions 
on the small and large intestinal mucosa were absent or markedly less severe in 
S. boulardii-treated mice; and (iii) there was no decrease in the number of C.",axenic,,,
158,22014083.txt,"Clostridium 
difficile (",mice,,,"Bacillus Coagulans GBI-30, 6086 (BC30)","All mice treated with BC30 survived on study day 13, while two mice 
treated with vehicle did not survive.",C57BL/6,VPI 10463,female,
159,22203600.txt,Clostridium difficile.,hamster,"selectively inhibits the replication-specific DNA 
polymerase of Clostridium difficile",,"N(2)-(3,4-Dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine (MorE-DCBG, 362E)","362E 
was as effective as oral vancomycin, the current agent of choice for treating 
severe forms of the human disease.",,,,
160,22264229.txt,Clostridium difficile toxin-induced,rabbit,,toxin A-induced,"combination therapy with ATL 370, an adenosine A2A receptor 
agonist, and alanyl-glutamine","Combination therapy with an adenosine A2A receptor agonist and 
alanyl-glutamine is effective in reversing C. difficile toxin A-induced 
epithelial injury, inflammation, secretion and apoptosis in animals and has 
therapeutic potential for the management of C. difficile infection.",,,,
161,22264229.txt,Clostridium difficile toxin-induced,murine,,toxin A-induced,"combination therapy with ATL 370, an adenosine A2A receptor 
agonist, and alanyl-glutamine","Combination therapy with an adenosine A2A receptor agonist and 
alanyl-glutamine is effective in reversing C. difficile toxin A-induced 
epithelial injury, inflammation, secretion and apoptosis in animals and has 
therapeutic potential for the management of C. difficile infection.",,,,
162,22431852.txt,Clostridium difficile infection,hamsters,,,oritavancin,"Orally administered oritavancin was more effective than vancomycin in 
Clostridium difficile infection in hamsters.",,,,
163,22431852.txt,Clostridium difficile infection,hamsters,,,vancomycin,"Orally administered oritavancin was more effective than vancomycin in 
Clostridium difficile infection in hamsters.",,,,
164,22585229.txt,Clostridium difficile infection,mice,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,amixicile,"amixicile showed slightly less protection than did vancomycin 
by day 5.",,,,
165,22585229.txt,Clostridium difficile infection,mice,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,amixicile,"optimized CDI model, amixicile showed equivalence to 
vancomycin and fidaxomicin at day 5 and there was significantly greater survival 
produced by amixicile than by the other drugs on day 12.",,,,
166,22585229.txt,Clostridium difficile infection,mice,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,amixicile,"Recurrence 
of CDI was common for mice treated with vancomycin or fidaxomicin but not for 
mice receiving amixicile or NTZ.",,,,
167,22585229.txt,Clostridium difficile infection,mice,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,vancomycin,"amixicile showed slightly less protection than did vancomycin 
by day 5.",,,,
168,22585229.txt,Clostridium difficile infection,mice,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,vancomycin,"optimized CDI model, amixicile showed equivalence to 
vancomycin and fidaxomicin at day 5 and there was significantly greater survival 
produced by amixicile than by the other drugs on day 12.",,,,
169,22585229.txt,Clostridium difficile infection,mice,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,vancomycin,"Recurrence 
of CDI was common for mice treated with vancomycin or fidaxomicin but not for 
mice receiving amixicile or NTZ.",,,,
170,22585229.txt,Clostridium difficile infection,mice,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,fidaxomicin,"amixicile showed slightly less protection than did vancomycin 
by day 5.",,,,
171,22585229.txt,Clostridium difficile infection,mice,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,fidaxomicin,"optimized CDI model, amixicile showed equivalence to 
vancomycin and fidaxomicin at day 5 and there was significantly greater survival 
produced by amixicile than by the other drugs on day 12.",,,,
172,22585229.txt,Clostridium difficile infection,mice,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,fidaxomicin,"Recurrence 
of CDI was common for mice treated with vancomycin or fidaxomicin but not for 
mice receiving amixicile or NTZ.",,,,
173,22585229.txt,Clostridium difficile infection,optimized CDI model,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,amixicile,"amixicile showed slightly less protection than did vancomycin 
by day 5.",,,,
174,22585229.txt,Clostridium difficile infection,optimized CDI model,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,amixicile,"optimized CDI model, amixicile showed equivalence to 
vancomycin and fidaxomicin at day 5 and there was significantly greater survival 
produced by amixicile than by the other drugs on day 12.",,,,
175,22585229.txt,Clostridium difficile infection,optimized CDI model,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,amixicile,"Recurrence 
of CDI was common for mice treated with vancomycin or fidaxomicin but not for 
mice receiving amixicile or NTZ.",,,,
176,22585229.txt,Clostridium difficile infection,optimized CDI model,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,vancomycin,"amixicile showed slightly less protection than did vancomycin 
by day 5.",,,,
177,22585229.txt,Clostridium difficile infection,optimized CDI model,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,vancomycin,"optimized CDI model, amixicile showed equivalence to 
vancomycin and fidaxomicin at day 5 and there was significantly greater survival 
produced by amixicile than by the other drugs on day 12.",,,,
178,22585229.txt,Clostridium difficile infection,optimized CDI model,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,vancomycin,"Recurrence 
of CDI was common for mice treated with vancomycin or fidaxomicin but not for 
mice receiving amixicile or NTZ.",,,,
179,22585229.txt,Clostridium difficile infection,optimized CDI model,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,fidaxomicin,"amixicile showed slightly less protection than did vancomycin 
by day 5.",,,,
180,22585229.txt,Clostridium difficile infection,optimized CDI model,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,fidaxomicin,"optimized CDI model, amixicile showed equivalence to 
vancomycin and fidaxomicin at day 5 and there was significantly greater survival 
produced by amixicile than by the other drugs on day 12.",,,,
181,22585229.txt,Clostridium difficile infection,optimized CDI model,"an inhibitor of pyruvate:ferredoxin 
oxidoreductase (PFOR)",,fidaxomicin,"Recurrence 
of CDI was common for mice treated with vancomycin or fidaxomicin but not for 
mice receiving amixicile or NTZ.",,,,
182,22644020.txt,Clostridium difficile.,hamster,,,LFF571,"data showed that 5 mg/kg LFF571 decreased the risk of 
death by 79% (P < 0.0001) and 69% (P = 0.0022) compared with saline and 20 mg/kg 
vancomycin, respectively.",Golden Syrian,,,
183,22644020.txt,Clostridium difficile.,hamster,,,LFF571,"Further analysis of the pooled data indicated that the 
survival benefit of LFF571 treatment at 5 mg/kg compared to vancomycin at 20 
mg/kg was due primarily to a decrease in the risk of recurrence after end of 
treatment.",Golden Syrian,,,
184,22733075.txt,Clostridium difficile infection,hamster,,,MBX-500,"MBX-500 was active in acute and recurrent 
infections in a toxigenic hamster model of CDI, exhibiting full protection 
against acute infections and prevention of recurrence in 70% of the animals.",,,,
185,22733075.txt,Clostridium difficile infection,murine,,,MBX-500,"MBX-500 was active in acute and recurrent 
infections in a toxigenic hamster model of CDI, exhibiting full protection 
against acute infections and prevention of recurrence in 70% of the animals.",,,,
186,22733075.txt,Clostridium difficile infection,hamster,,,MBX-500,"MBX-500 was efficacious in a murine 
model of CDI, again demonstrating a fully protective effect and permitting 
near-normal weight gain in the treated animals.",,,,
187,22733075.txt,Clostridium difficile infection,murine,,,MBX-500,"MBX-500 was efficacious in a murine 
model of CDI, again demonstrating a fully protective effect and permitting 
near-normal weight gain in the treated animals.",,,,
188,22733075.txt,"acute and recurrent 
infections",hamster,,,MBX-500,"MBX-500 was active in acute and recurrent 
infections in a toxigenic hamster model of CDI, exhibiting full protection 
against acute infections and prevention of recurrence in 70% of the animals.",,,,
189,22733075.txt,"acute and recurrent 
infections",murine,,,MBX-500,"MBX-500 was active in acute and recurrent 
infections in a toxigenic hamster model of CDI, exhibiting full protection 
against acute infections and prevention of recurrence in 70% of the animals.",,,,
190,22733075.txt,"acute and recurrent 
infections",hamster,,,MBX-500,"MBX-500 was efficacious in a murine 
model of CDI, again demonstrating a fully protective effect and permitting 
near-normal weight gain in the treated animals.",,,,
191,22733075.txt,"acute and recurrent 
infections",murine,,,MBX-500,"MBX-500 was efficacious in a murine 
model of CDI, again demonstrating a fully protective effect and permitting 
near-normal weight gain in the treated animals.",,,,
192,22760006.txt,"Clostridium 
difficile infection",mice,,antibiotic mixture and infected orally with C difficile.,mCRAMP,"Intracolonic mCRAMP administration to C difficile-infected WT mice 
showed significantly reduced colonic histology damage, apoptosis, tissue 
myeloperoxidase (MPO) and tumour necrosis factor (TNF)α levels.",Wild-type (WT),,,
193,22760006.txt,"Clostridium 
difficile infection",mice,,antibiotic mixture and infected orally with C difficile.,mCRAMP,"Ileal mCRAMP 
treatment also significantly reduced histology damage, tissue apoptosis, MPO and 
TNFα levels in TxA-exposed ileal loops.",Wild-type (WT),,,
194,22760006.txt,"Clostridium 
difficile infection",mice,,Ileal loops,mCRAMP,"Intracolonic mCRAMP administration to C difficile-infected WT mice 
showed significantly reduced colonic histology damage, apoptosis, tissue 
myeloperoxidase (MPO) and tumour necrosis factor (TNF)α levels.",Wild-type (WT),,,
195,22760006.txt,"Clostridium 
difficile infection",mice,,Ileal loops,mCRAMP,"Ileal mCRAMP 
treatment also significantly reduced histology damage, tissue apoptosis, MPO and 
TNFα levels in TxA-exposed ileal loops.",Wild-type (WT),,,
196,22802252.txt,"Clostridium difficile-associated 
diarrhea",hamster,,,"CB-183,315 is a novel lipopeptide antibiotic structurally related to daptomycin","In the hamster model of CDAD, CB-183,315 and vancomycin both demonstrated potent 
efficacy in resolving initial disease onset, even at very low doses.",,,,
197,22802252.txt,"Clostridium difficile-associated 
diarrhea",hamster,,,"CB-183,315 is a novel lipopeptide antibiotic structurally related to daptomycin","After the 
conclusion of dosing, CB-183,315 and vancomycin showed a similar dose- and 
time-dependent pattern with respect to rates of CDAD recurrence.",,,,
198,22802252.txt,"Clostridium difficile-associated 
diarrhea",hamster,,,vancomycin,"In the hamster model of CDAD, CB-183,315 and vancomycin both demonstrated potent 
efficacy in resolving initial disease onset, even at very low doses.",,,,
199,22802252.txt,"Clostridium difficile-associated 
diarrhea",hamster,,,vancomycin,"After the 
conclusion of dosing, CB-183,315 and vancomycin showed a similar dose- and 
time-dependent pattern with respect to rates of CDAD recurrence.",,,,
200,22802252.txt,"Clostridium difficile-associated 
diarrhea",hamster,,,vancomycin,"In the hamster model of CDAD, CB-183,315 and vancomycin both demonstrated potent 
efficacy in resolving initial disease onset, even at very low doses.",,,,
201,22802252.txt,"Clostridium difficile-associated 
diarrhea",hamster,,,vancomycin,"After the 
conclusion of dosing, CB-183,315 and vancomycin showed a similar dose- and 
time-dependent pattern with respect to rates of CDAD recurrence.",,,,
202,22869573.txt,Clostridium difficile,hamster,,,RBx 14255,"Furthermore, in the hamster 
model of C. difficile infection, RBx 14255 demonstrated greater efficacy than 
metronidazole and vancomycin, making it a promising candidate for C. difficile 
treatment.",,,,
203,22890996.txt,Clostridium difficile,Mice,,antibiotic-treated,E. coli strains,"Infection of 
germfree mice or mice precolonized with E. coli with C. difficile strain VPI 
10463 was uniformly fatal by 48 h, but only 20% mortality was seen at 2 days in 
mice precolonized with the Lachnospiraceae isolate prior to challenge with VPI 
10463.",germfree,"VPI 
10463",,
204,22890996.txt,Clostridium difficile,Mice,,antibiotic-treated,"murine 
Lachnospiraceae isolate","Infection of 
germfree mice or mice precolonized with E. coli with C. difficile strain VPI 
10463 was uniformly fatal by 48 h, but only 20% mortality was seen at 2 days in 
mice precolonized with the Lachnospiraceae isolate prior to challenge with VPI 
10463.",germfree,"VPI 
10463",,
205,22895082.txt,Clostridium difficile.,mice,,,viable S. thermophilus,"In the context of infection with C. difficile, mice treated with 
viable S. thermophilus exhibited 46% less weight loss compared with untreated 
controls; moreover, less pathology, diarrhea, and lower detectable toxin levels 
in cecal contents were evident more often in S. thermophillus treated mice.",,,,
206,22899803.txt,Clostridium difficile infection,hamster,,,oritavancin,"All hamsters treated with oritavancin survived up to 20 days, with no 
evidence of C. difficile spores, vegetative cells or toxin in their caeca.",,,,
207,22899803.txt,Clostridium difficile infection,hamster,,,oritavancin,"No 
hamsters treated with clindamycin or vancomycin survived >6 days after spore 
administration.",,,,
208,22899803.txt,Clostridium difficile infection,hamster,,,vancomycin,"All hamsters treated with oritavancin survived up to 20 days, with no 
evidence of C. difficile spores, vegetative cells or toxin in their caeca.",,,,
209,22899803.txt,Clostridium difficile infection,hamster,,,vancomycin,"No 
hamsters treated with clindamycin or vancomycin survived >6 days after spore 
administration.",,,,
210,22899803.txt,Clostridium difficile infection,hamster,,,clindamycin,"All hamsters treated with oritavancin survived up to 20 days, with no 
evidence of C. difficile spores, vegetative cells or toxin in their caeca.",,,,
211,22899803.txt,Clostridium difficile infection,hamster,,,clindamycin,"No 
hamsters treated with clindamycin or vancomycin survived >6 days after spore 
administration.",,,,
212,23045479.txt,Clostridium difficile,rabbits,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,wild-type,,,ATL692
213,23045479.txt,Clostridium difficile,rabbits,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",wild-type,,,ATL692
214,23045479.txt,Clostridium difficile,rabbits,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,wild-type,,,ATL692
215,23045479.txt,Clostridium difficile,rabbits,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",wild-type,,,ATL692
216,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,wild-type,,,ATL692
217,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",wild-type,,,ATL692
218,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,wild-type,,,ATL692
219,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",wild-type,,,ATL692
220,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,wild-type,,,ATL692
221,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",wild-type,,,ATL692
222,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,wild-type,,,ATL692
223,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",wild-type,,,ATL692
224,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,wild-type,,,ATL692
225,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",wild-type,,,ATL692
226,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,wild-type,,,ATL692
227,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",wild-type,,,ATL692
228,23045479.txt,Clostridium difficile,rabbits,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,A(2B)AR(-/-),,,ATL692
229,23045479.txt,Clostridium difficile,rabbits,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",A(2B)AR(-/-),,,ATL692
230,23045479.txt,Clostridium difficile,rabbits,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,A(2B)AR(-/-),,,ATL692
231,23045479.txt,Clostridium difficile,rabbits,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",A(2B)AR(-/-),,,ATL692
232,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,A(2B)AR(-/-),,,ATL692
233,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",A(2B)AR(-/-),,,ATL692
234,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,A(2B)AR(-/-),,,ATL692
235,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",A(2B)AR(-/-),,,ATL692
236,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,A(2B)AR(-/-),,,ATL692
237,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",A(2B)AR(-/-),,,ATL692
238,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,A(2B)AR(-/-),,,ATL692
239,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",A(2B)AR(-/-),,,ATL692
240,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,A(2B)AR(-/-),,,ATL692
241,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL692,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",A(2B)AR(-/-),,,ATL692
242,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,ATL692 decreased TcdA-induced secretion and epithelial injury in rabbit ileum.,A(2B)AR(-/-),,,ATL692
243,23045479.txt,Clostridium difficile,mice,A(2B)AR antagonist,"Ileal loops from wild-type rabbits and mice and A(2B)AR(-/-) mice 
were treated with TcdA",ATL801,"Deletion or blockade of A(2B)ARs reduced histopathology, IL-6 
expression, weight loss, diarrhea, and mortality in C. difficile-infected mice.",A(2B)AR(-/-),,,ATL692
244,23071818.txt,"C. difficile-associated disease (CDAD),",mice,PPARγ agonist,,pioglitazone,"Oral treatment of C. difficile-infected mice with the 
PPARγ agonist pioglitazone ameliorated colitis and suppressed pro-inflammatory 
gene expression.",wild-type,,,
245,23133377.txt,Relapsing C. difficile,mice,,,vancomycin,"Chronic C. difficile 
027/BI infection was refractory to vancomycin treatment leading to relapsing 
disease.",,027/BI,,
246,23133377.txt,Relapsing C. difficile,mice,,,"feces 
from healthy mice","Chronic C. difficile 
027/BI infection was refractory to vancomycin treatment leading to relapsing 
disease.",,027/BI,,
247,23133377.txt,Relapsing C. difficile,mice,,,vancomycin,"treatment of C. difficile 027/BI infected mice with feces 
from healthy mice rapidly restored a diverse, healthy microbiota",,027/BI,,
248,23133377.txt,Relapsing C. difficile,mice,,,"feces 
from healthy mice","treatment of C. difficile 027/BI infected mice with feces 
from healthy mice rapidly restored a diverse, healthy microbiota",,027/BI,,
249,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,vancomycin,"Vancomycin treatment of 
infected mice was associated with improved clinical, diarrhea, and 
histopathology scores and survival during treatment.",C57BL/6,VPI 10463,,
250,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,vancomycin,"However, after 
discontinuation of the drug, clinical scores and histopathology were worse in 
treated mice than in untreated infected controls.",C57BL/6,VPI 10463,,
251,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,vancomycin,"Fidaxomicin-treated mice had outcomes similar to those of vancomycin-treated 
mice.",C57BL/6,VPI 10463,,
252,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,nitazoxanide,"Vancomycin treatment of 
infected mice was associated with improved clinical, diarrhea, and 
histopathology scores and survival during treatment.",C57BL/6,VPI 10463,,
253,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,nitazoxanide,"However, after 
discontinuation of the drug, clinical scores and histopathology were worse in 
treated mice than in untreated infected controls.",C57BL/6,VPI 10463,,
254,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,nitazoxanide,"Fidaxomicin-treated mice had outcomes similar to those of vancomycin-treated 
mice.",C57BL/6,VPI 10463,,
255,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,fidaxomicin,"Vancomycin treatment of 
infected mice was associated with improved clinical, diarrhea, and 
histopathology scores and survival during treatment.",C57BL/6,VPI 10463,,
256,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,fidaxomicin,"However, after 
discontinuation of the drug, clinical scores and histopathology were worse in 
treated mice than in untreated infected controls.",C57BL/6,VPI 10463,,
257,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,fidaxomicin,"Fidaxomicin-treated mice had outcomes similar to those of vancomycin-treated 
mice.",C57BL/6,VPI 10463,,
258,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,metronidazaole,"Vancomycin treatment of 
infected mice was associated with improved clinical, diarrhea, and 
histopathology scores and survival during treatment.",C57BL/6,VPI 10463,,
259,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,metronidazaole,"However, after 
discontinuation of the drug, clinical scores and histopathology were worse in 
treated mice than in untreated infected controls.",C57BL/6,VPI 10463,,
260,23147742.txt,Clostridium difficile infection,mice,,pretreatment with an antibiotic cocktail.,metronidazaole,"Fidaxomicin-treated mice had outcomes similar to those of vancomycin-treated 
mice.",C57BL/6,VPI 10463,,
261,23183468.txt,"Clostridium 
difficile associated disease",mice,,,probiotic,"Probiotics showed their beneficial effect by boosting the immune 
response as seen by production of antitoxin IgG.",BALB/c,,,
262,23183468.txt,"Clostridium 
difficile associated disease",mice,,,probiotic,"administration of EGF did 
not affect the immune response to C. difficile toxins as significant increase 
was not observed in the serum antitoxin IgG levels in any of the groups 
investigated.",BALB/c,,,
263,23183468.txt,"Clostridium 
difficile associated disease",mice,,,epidermal growth factor,"Probiotics showed their beneficial effect by boosting the immune 
response as seen by production of antitoxin IgG.",BALB/c,,,
264,23183468.txt,"Clostridium 
difficile associated disease",mice,,,epidermal growth factor,"administration of EGF did 
not affect the immune response to C. difficile toxins as significant increase 
was not observed in the serum antitoxin IgG levels in any of the groups 
investigated.",BALB/c,,,
265,23183468.txt,"Clostridium 
difficile associated disease",mice,,,ampicillin,"Probiotics showed their beneficial effect by boosting the immune 
response as seen by production of antitoxin IgG.",BALB/c,,,
266,23183468.txt,"Clostridium 
difficile associated disease",mice,,,ampicillin,"administration of EGF did 
not affect the immune response to C. difficile toxins as significant increase 
was not observed in the serum antitoxin IgG levels in any of the groups 
investigated.",BALB/c,,,
267,23183468.txt,"Clostridium 
difficile associated disease",mice,,,lansoprazole,"Probiotics showed their beneficial effect by boosting the immune 
response as seen by production of antitoxin IgG.",BALB/c,,,
268,23183468.txt,"Clostridium 
difficile associated disease",mice,,,lansoprazole,"administration of EGF did 
not affect the immune response to C. difficile toxins as significant increase 
was not observed in the serum antitoxin IgG levels in any of the groups 
investigated.",BALB/c,,,
269,23183468.txt,"Clostridium 
difficile associated disease",mice,,,cyclosporin,"Probiotics showed their beneficial effect by boosting the immune 
response as seen by production of antitoxin IgG.",BALB/c,,,
270,23183468.txt,"Clostridium 
difficile associated disease",mice,,,cyclosporin,"administration of EGF did 
not affect the immune response to C. difficile toxins as significant increase 
was not observed in the serum antitoxin IgG levels in any of the groups 
investigated.",BALB/c,,,
271,23217055.txt,C. difficile,mice,,antibiotic cocktail,vancomycin,"Infected mice treated with both 
vancomycin and an A2AAR agonist, either ATL370 or ATL1222, had minimal weight 
loss and better long-term survival than mice treated with vancomycin alone.",C57BL/6,VPI10463,,
272,23217055.txt,C. difficile,mice,,antibiotic cocktail,ATL370,"Infected mice treated with both 
vancomycin and an A2AAR agonist, either ATL370 or ATL1222, had minimal weight 
loss and better long-term survival than mice treated with vancomycin alone.",C57BL/6,VPI10463,,
273,23217055.txt,C. difficile,mice,,antibiotic cocktail,ATL1222,"Infected mice treated with both 
vancomycin and an A2AAR agonist, either ATL370 or ATL1222, had minimal weight 
loss and better long-term survival than mice treated with vancomycin alone.",C57BL/6,VPI10463,,
274,23324518.txt,Clostridium difficile,hamster,,,mixture of three humanized IgG1 monoclonal antibodies,"The UCB MAb mixture showed higher potency in a variety 
of in vitro binding and neutralization assays (∼10-fold improvements), higher 
levels of protection in a hamster model of CDI (82% versus 18% at 28 days), and 
higher valencies of toxin binding (12 versus 2 for TcdA and 3 versus 2 for TcdB) 
than other agents in clinical development.",,,,
275,23359592.txt,,mice,,,Clostridium difficile,"Infected mice treated with vancomycin and AQ had better 
survival and histopathologic findings than mice treated with vancomycin alone.",C57BL/6,"VPI 
10463",,
276,23359592.txt,,mice,,,Alanyl-glutamine,"Infected mice treated with vancomycin and AQ had better 
survival and histopathologic findings than mice treated with vancomycin alone.",C57BL/6,"VPI 
10463",,
277,23359592.txt,,mice,,,vancomycin,"Infected mice treated with vancomycin and AQ had better 
survival and histopathologic findings than mice treated with vancomycin alone.",C57BL/6,"VPI 
10463",,
278,23359592.txt,,mice,,,vancomycin with AQ,"Infected mice treated with vancomycin and AQ had better 
survival and histopathologic findings than mice treated with vancomycin alone.",C57BL/6,"VPI 
10463",,
279,23420906.txt,Clostridium difficile infection,Mice,,,CamSA,"A single 50-mg/kg dose of CamSA prevented CDI in mice without any 
observable toxicity.",,,,
280,23542116.txt,Clostridium difficile,hamster,,clyndamicin,"mixture (MM) 
constituted by kefir-isolated microorganisms (Lactobacillus plantarum, 
Lactobacillus kefir, Lc. lactis, Kluyveromyces marxianus and Saccharomyces 
cerevisiae)","an oral 
treatment with a mixture of kefir-isolated bacteria and yeasts was able to 
prevent diarrhoea and enterocolitis triggered by C. difficile.",,,,
281,23598380.txt,Clostridium difficile.,mice,,antibiotic(s),calf IAP (cIAP),"Oral IAP supplementation protected mice from antibiotic-associated 
bacterial infections.",C57BL/6,,,
282,23611644.txt,Clostridium difficile infection,hamster,,clindamycin,Bifidobacterium,"the infected animals 
belonging to the placebo group developed enterocolitis (5/5) and only two dead 
(2/5) whereas in the group administered with Bifidobacterium bifidum strain 
CIDCA 5310 the ratio of animals with enterocolitis or dead decreased 
significantly (1/5 and 0/5 respectively).",,,,
283,23611644.txt,Clostridium difficile infection,hamster,,clindamycin,"Strains 
CIDCA 531, CIDCA 5310, CIDCA 5316, CIDCA 5320, CIDCA 5323 and CIDCA 5325","the infected animals 
belonging to the placebo group developed enterocolitis (5/5) and only two dead 
(2/5) whereas in the group administered with Bifidobacterium bifidum strain 
CIDCA 5310 the ratio of animals with enterocolitis or dead decreased 
significantly (1/5 and 0/5 respectively).",,,,
284,23689716.txt,Clostridium difficile infection,pig,,gnotobiotic pig model.,MBX-500,"MBX-500 increased survival at all doses and at 
high doses improved clinical signs and reduced lesion severity, similar to 
vancomycin.",,,,
285,23897615.txt,Clostridium difficile,mice,,,"Antibody 
neutralization of CXCL1 and CXCL2","Additionally, low serum levels of CXCL1 and CXCL2 corresponded with 
greater survival.",,,,
286,23995682.txt,Clostridium difficile,mice,,,"sialidase-deficient mutant of 
Bacteroides thetaiotaomicron","Colonization of gnotobiotic mice with a sialidase-deficient mutant of 
Bacteroides thetaiotaomicron, a model gut symbiont, reduces free sialic acid 
levels resulting in C. difficile downregulating its sialic acid catabolic 
pathway and exhibiting impaired expansion.",gnotobiotic,,,
287,24023628.txt,Clostridium difficile infection,mouse,,,CamSA,"CamSA, a synthetic bile salt 
analog, inhibits C. difficile spore germination in vitro and in vivo.",,,,
288,24277020.txt,Clostridium difficile,hamster,,,Cadazolid,"In the hamster and mouse 
models for CDAD, cadazolid was active, conferring full protection from diarrhea 
and death with a potency similar to that of vancomycin.",,,,
289,24277020.txt,Clostridium difficile,mouse,,,Cadazolid,"In the hamster and mouse 
models for CDAD, cadazolid was active, conferring full protection from diarrhea 
and death with a potency similar to that of vancomycin.",,,,
290,24278446.txt,C. difficile,mice,,,P2Y6 receptor antagonists (MSR2578),"Lastly, pretreating mice with the 
P2Y6 receptor antagonists (MSR2578) attenuated TcdA/B-induced inflammation and 
intestinal permeability in an intrarectal toxin exposure model.",,,,
291,24287693.txt,Clostridium difficile.,mice,,,Thuricin CD,"When thuricin CD was delivered rectally to mice (n = 40) and C. difficile 
shedding monitored at 1, 6, 12 and 24 h post-treatment, there was a >95 % (>1.5 
log units) reduction of C. difficile 027 in the colon contents of infected mice 
(n = 10) 1 h post-treatment compared with the control group (n = 10; P<0.001).",,. difficile 027,,
292,24509250.txt,Clostridium difficile,mouse,,toxin-A-treated mouse model.,antitoxin sera,"antitoxin serum has 
biotherapeutic effects in preventing various C. difficile toxin-A-induced 
cellular toxicities.",,,,
293,24514098.txt,C. difficile-associated diarrhea,hamster,inhibitor of type II topoisomerase enzymes,,Kibdelomycin,"Dosing at 1.6 mg/kg (twice-daily oral dose) resulted in protection from 
a lethal infection and a 2-log reduction in C. difficile cecal counts.",,,,
294,24590475.txt,Clostridium difficile infection,mice,,,Tigecycline,"Mice with tigecycline-altered microbial 
communities were susceptible to challenge with C. difficile spores and developed 
clinical signs of severe CDI.",,VPI 10463,,
295,24683195.txt,Clostridium difficile infection,mice,,,"tetravalent, and bispecific antibody composed of 2 
heavy-chain-only VH (VHH) binding domains against both TcdA and TcdB (designated 
""ABA"")","Additionally, ABA was able to broadly 
neutralize toxins from clinical C. difficile isolates that express both TcdA and 
TcdB but failed to neutralize the toxin from TcdA(-)TcdB(+) C. difficile 
strains.",,epidemic 027 strain,,
296,24828432.txt,Clostridium difficile,murine,,,B. subtilis,"Using a murine model of infection, we demonstrate that 
oral administration of B. subtilis spores can attenuate the symptoms of 
infection.",,,,
297,24837414.txt,C. difficile infection (CDI),murine,,,"5-nitro-1,10-phenanthroline (5-NP)","preliminary evidence suggests moderate efficacy for this compound 
in treating CDI in a murine infection model.",,,,
298,24856984.txt,Clostridium difficile,mice,,,L. acidophilus GP1B cell extract,"Both the L. acidophilus 
GP1B and GP1B cell extract have significant antipathogenic effects on C.",,,,
299,24856984.txt,Clostridium difficile,mice,,,L. acidophilus GP1B,"Both the L. acidophilus 
GP1B and GP1B cell extract have significant antipathogenic effects on C.",,,,
300,24890583.txt,Clostridium difficile infection,mice,,ileal loops,fidaxomicin,"Treatment with fidaxomicin 
(20 μM) or its primary metabolite, OP-1118 (120 μM), significantly inhibited 
toxin A-mediated histologic damage and reduced the mean histology score and 
ileal IL-1β protein and mRNA expression.",,,,
301,24890583.txt,Clostridium difficile infection,mice,,ileal loops,fidaxomicin,"Treatment 
of ileal loops with vancomycin (20 μM) and metronidazole (20 μM) did not alter 
toxin A-induced histologic damage and IL-1β protein expression.",,,,
302,24890583.txt,Clostridium difficile infection,mice,,ileal loops,vancomycin,"Treatment with fidaxomicin 
(20 μM) or its primary metabolite, OP-1118 (120 μM), significantly inhibited 
toxin A-mediated histologic damage and reduced the mean histology score and 
ileal IL-1β protein and mRNA expression.",,,,
303,24890583.txt,Clostridium difficile infection,mice,,ileal loops,vancomycin,"Treatment 
of ileal loops with vancomycin (20 μM) and metronidazole (20 μM) did not alter 
toxin A-induced histologic damage and IL-1β protein expression.",,,,
304,24890583.txt,Clostridium difficile infection,mice,,ileal loops,metronidazole,"Treatment with fidaxomicin 
(20 μM) or its primary metabolite, OP-1118 (120 μM), significantly inhibited 
toxin A-mediated histologic damage and reduced the mean histology score and 
ileal IL-1β protein and mRNA expression.",,,,
305,24890583.txt,Clostridium difficile infection,mice,,ileal loops,metronidazole,"Treatment 
of ileal loops with vancomycin (20 μM) and metronidazole (20 μM) did not alter 
toxin A-induced histologic damage and IL-1β protein expression.",,,,
306,24890599.txt,Clostridium difficile infections,mouse,,,Amixicile,"Amixicile shows efficacy in the treatment of Clostridium difficile infections 
(CDI) in a mouse model, with no recurrence of CDI.",,,,
307,25022586.txt,Clostridium difficile infection.,hamster,,,"SMT19969 [2,2'-bis(4-pyridyl)3H,3'-H 5,5-bibenzimidazole]","Vancomycin exhibited 100% protection during treatment, with relapse observed 
starting on day 9 and 50% survival at day 20.",,,,
308,25022586.txt,Clostridium difficile infection.,hamster,,,"SMT19969 [2,2'-bis(4-pyridyl)3H,3'-H 5,5-bibenzimidazole]","At 50 mg/kg of body weight, 
SMT19969 administered orally once daily for 5 days provided full protection of 
treated animals on the dosing days and through day 12 against epidemic strains.",,,,
309,25022586.txt,Clostridium difficile infection.,hamster,,,Vancomycin,"Vancomycin exhibited 100% protection during treatment, with relapse observed 
starting on day 9 and 50% survival at day 20.",,,,
310,25022586.txt,Clostridium difficile infection.,hamster,,,Vancomycin,"At 50 mg/kg of body weight, 
SMT19969 administered orally once daily for 5 days provided full protection of 
treated animals on the dosing days and through day 12 against epidemic strains.",,,,
311,25036923.txt,Clostridium difficile infections,hamsters,,clindamycin,fecal extracts,"C. difficile culture 
growth and toxin production were inhibited by the presence of fecal extracts 
from untreated hamsters but not extracts collected 5 days post-administration of 
clindamycin.","Syrian 
golden",,,
312,25045999.txt,Clostridium difficile infection,mice,,Cefoperazone-treated,monoclonal antibody (mAb) against GM-CSF,"These data indicate that GM-CSF 
plays a role in the inflammatory signaling network that drives neutrophil 
recruitment in response to C. difficile infection but does not appear to play a 
role in clearance of the infection.",,strain 630,,
313,25059277.txt,Clostridium difficile (,mice,,,synbiotic formulation,"synbiotic or multi-strain probiotic formulation confers protection against 
NAP1/027 infection in C57BL/6 mice.",C57BL/6,NAP1/027,,
314,25129314.txt,Clostridium difficile infection,murine,,,metronidazole,"Results show that whilst transient resistance occurs to 
metronidazole and nitazoxanide, stable resistance arises to nitrofurans upon 
serial passage.",,,,
315,25129314.txt,Clostridium difficile infection,murine,,,nitazoxanide,"Results show that whilst transient resistance occurs to 
metronidazole and nitazoxanide, stable resistance arises to nitrofurans upon 
serial passage.",,,,
316,25129314.txt,Clostridium difficile infection,murine,,,nitrofurans,"Results show that whilst transient resistance occurs to 
metronidazole and nitazoxanide, stable resistance arises to nitrofurans upon 
serial passage.",,,,
317,25129314.txt,Clostridium difficile infection,murine,,,metronidazole,"All compounds killed C. difficile at high concentrations in 
addition to the host defence nitrosating agent S-nitrosoglutathione (GSNO).",,,,
318,25129314.txt,Clostridium difficile infection,murine,,,nitazoxanide,"All compounds killed C. difficile at high concentrations in 
addition to the host defence nitrosating agent S-nitrosoglutathione (GSNO).",,,,
319,25129314.txt,Clostridium difficile infection,murine,,,nitrofurans,"All compounds killed C. difficile at high concentrations in 
addition to the host defence nitrosating agent S-nitrosoglutathione (GSNO).",,,,
320,25267665.txt,Clostridium difficile infection,pig,,"gnotobiotic pig 
model",tigecycline,"Tigecycline oral treatment improved survival, clinical 
signs, and lesion severity",,,,
321,25267665.txt,Clostridium difficile infection,pig,,human gut microflora transplanted,tigecycline,"Tigecycline oral treatment improved survival, clinical 
signs, and lesion severity",,,,
322,25327211.txt,Clostridium difficile infection,mice,,,"anti-IL-22, anti-CD160 or a combination of the two","They also underscore 
the additive effects of IL-22 and CD160 in mediating both the pro-inflammatory 
and pro-survival aspects of the host mucosal response in this infection.",,,,
323,25399934.txt,Clostridium difficile infection,mice,,ceftriaxone,monoclonal antibodies against Gr-1 or TNF-α,"These studies raise the 
possibility that TNF-α may play a role in restraining inflammation and 
protecting the epithelium during C. difficile infection.",,VPI 10463,,
324,25486992.txt,Clostridium difficile infection,murine,,systemic,"combination of human monoclonal antibodies, 
actoxumab and bezlotoxumab","Systemically administered actoxumab-bezlotoxumab prevents 
both the damage to the gut wall and the inflammatory response, which are 
associated with C. difficile in these models, including in mice challenged with 
a strain of the hypervirulent ribotype 027.",,,,
325,25486992.txt,Clostridium difficile infection,murine,,local (gut) toxin challenge models,"combination of human monoclonal antibodies, 
actoxumab and bezlotoxumab","Systemically administered actoxumab-bezlotoxumab prevents 
both the damage to the gut wall and the inflammatory response, which are 
associated with C. difficile in these models, including in mice challenged with 
a strain of the hypervirulent ribotype 027.",,,,
326,25486992.txt,Clostridium difficile infection,murine,,primary and recurrent models,"combination of human monoclonal antibodies, 
actoxumab and bezlotoxumab","Systemically administered actoxumab-bezlotoxumab prevents 
both the damage to the gut wall and the inflammatory response, which are 
associated with C. difficile in these models, including in mice challenged with 
a strain of the hypervirulent ribotype 027.",,,,
327,25547352.txt,Clostridium difficile.,mice,,,tigecycline,"Toxin activity and 
histopathological inflammation and edema were observed in the ceca and colons of 
untreated mice; tigecycline- and vancomycin-treated mice did not show such 
changes directly after treatment.",C57BL/6,C. difficile strain 630,,
328,25547352.txt,Clostridium difficile.,mice,,,tigecycline,"One week after the conclusion of either 
antibiotic treatment, C. difficile load, toxin activity, and histopathology 
scores increased in the cecum and colon, indicating that C. difficile-associated 
disease occurred.",C57BL/6,C. difficile strain 630,,
329,25547352.txt,Clostridium difficile.,mice,,,vancomycin,"Toxin activity and 
histopathological inflammation and edema were observed in the ceca and colons of 
untreated mice; tigecycline- and vancomycin-treated mice did not show such 
changes directly after treatment.",C57BL/6,C. difficile strain 630,,
330,25547352.txt,Clostridium difficile.,mice,,,vancomycin,"One week after the conclusion of either 
antibiotic treatment, C. difficile load, toxin activity, and histopathology 
scores increased in the cecum and colon, indicating that C. difficile-associated 
disease occurred.",C57BL/6,C. difficile strain 630,,
331,25652749.txt,Clostridium difficile infection,Hamsters,,,SMT19969,"Following infection with C. difficile BI1, treatment with SMT19969, 
vancomycin and fidaxomicin resulted in 100% survival during the 5 day dosing 
period, with 90%-100% of animals receiving SMT19969 and fidaxomicin surviving 
during the post-dosing follow-up period.",,C. difficile BI1,,
332,25652749.txt,Clostridium difficile infection,Hamsters,,,SMT19969,"Whilst protective during treatment, 
onset of mortality was observed on day 11 in animals treated with vancomycin, 
with a 10% survival recorded by day 28.",,C. difficile BI1,,
333,25652749.txt,Clostridium difficile infection,Hamsters,,,SMT19969,"Similar results were observed for 
SMT19969 and vancomycin following infection with C. difficile 630, with day 28 
survival rates of 80%-100% and 0%, respectively.",,C. difficile BI1,,
334,25652749.txt,Clostridium difficile infection,Hamsters,,,SMT19969,"Fidaxomicin protected animals 
infected with C. difficile 630 from mortality during dosing, although day 28 
survival rates varied from 0% to 40% depending on dose.",,C. difficile BI1,,
335,25652749.txt,Clostridium difficile infection,Hamsters,,,fidaxomicin,"Following infection with C. difficile BI1, treatment with SMT19969, 
vancomycin and fidaxomicin resulted in 100% survival during the 5 day dosing 
period, with 90%-100% of animals receiving SMT19969 and fidaxomicin surviving 
during the post-dosing follow-up period.",,C. difficile BI1,,
336,25652749.txt,Clostridium difficile infection,Hamsters,,,fidaxomicin,"Whilst protective during treatment, 
onset of mortality was observed on day 11 in animals treated with vancomycin, 
with a 10% survival recorded by day 28.",,C. difficile BI1,,
337,25652749.txt,Clostridium difficile infection,Hamsters,,,fidaxomicin,"Similar results were observed for 
SMT19969 and vancomycin following infection with C. difficile 630, with day 28 
survival rates of 80%-100% and 0%, respectively.",,C. difficile BI1,,
338,25652749.txt,Clostridium difficile infection,Hamsters,,,fidaxomicin,"Fidaxomicin protected animals 
infected with C. difficile 630 from mortality during dosing, although day 28 
survival rates varied from 0% to 40% depending on dose.",,C. difficile BI1,,
339,25652749.txt,Clostridium difficile infection,Hamsters,,,vancomycin,"Following infection with C. difficile BI1, treatment with SMT19969, 
vancomycin and fidaxomicin resulted in 100% survival during the 5 day dosing 
period, with 90%-100% of animals receiving SMT19969 and fidaxomicin surviving 
during the post-dosing follow-up period.",,C. difficile BI1,,
340,25652749.txt,Clostridium difficile infection,Hamsters,,,vancomycin,"Whilst protective during treatment, 
onset of mortality was observed on day 11 in animals treated with vancomycin, 
with a 10% survival recorded by day 28.",,C. difficile BI1,,
341,25652749.txt,Clostridium difficile infection,Hamsters,,,vancomycin,"Similar results were observed for 
SMT19969 and vancomycin following infection with C. difficile 630, with day 28 
survival rates of 80%-100% and 0%, respectively.",,C. difficile BI1,,
342,25652749.txt,Clostridium difficile infection,Hamsters,,,vancomycin,"Fidaxomicin protected animals 
infected with C. difficile 630 from mortality during dosing, although day 28 
survival rates varied from 0% to 40% depending on dose.",,C. difficile BI1,,
343,25652749.txt,Clostridium difficile infection,Hamsters,,,SMT19969,"Following infection with C. difficile BI1, treatment with SMT19969, 
vancomycin and fidaxomicin resulted in 100% survival during the 5 day dosing 
period, with 90%-100% of animals receiving SMT19969 and fidaxomicin surviving 
during the post-dosing follow-up period.",,C. difficile 630,,
344,25652749.txt,Clostridium difficile infection,Hamsters,,,SMT19969,"Whilst protective during treatment, 
onset of mortality was observed on day 11 in animals treated with vancomycin, 
with a 10% survival recorded by day 28.",,C. difficile 630,,
345,25652749.txt,Clostridium difficile infection,Hamsters,,,SMT19969,"Similar results were observed for 
SMT19969 and vancomycin following infection with C. difficile 630, with day 28 
survival rates of 80%-100% and 0%, respectively.",,C. difficile 630,,
346,25652749.txt,Clostridium difficile infection,Hamsters,,,SMT19969,"Fidaxomicin protected animals 
infected with C. difficile 630 from mortality during dosing, although day 28 
survival rates varied from 0% to 40% depending on dose.",,C. difficile 630,,
347,25652749.txt,Clostridium difficile infection,Hamsters,,,fidaxomicin,"Following infection with C. difficile BI1, treatment with SMT19969, 
vancomycin and fidaxomicin resulted in 100% survival during the 5 day dosing 
period, with 90%-100% of animals receiving SMT19969 and fidaxomicin surviving 
during the post-dosing follow-up period.",,C. difficile 630,,
348,25652749.txt,Clostridium difficile infection,Hamsters,,,fidaxomicin,"Whilst protective during treatment, 
onset of mortality was observed on day 11 in animals treated with vancomycin, 
with a 10% survival recorded by day 28.",,C. difficile 630,,
349,25652749.txt,Clostridium difficile infection,Hamsters,,,fidaxomicin,"Similar results were observed for 
SMT19969 and vancomycin following infection with C. difficile 630, with day 28 
survival rates of 80%-100% and 0%, respectively.",,C. difficile 630,,
350,25652749.txt,Clostridium difficile infection,Hamsters,,,fidaxomicin,"Fidaxomicin protected animals 
infected with C. difficile 630 from mortality during dosing, although day 28 
survival rates varied from 0% to 40% depending on dose.",,C. difficile 630,,
351,25652749.txt,Clostridium difficile infection,Hamsters,,,vancomycin,"Following infection with C. difficile BI1, treatment with SMT19969, 
vancomycin and fidaxomicin resulted in 100% survival during the 5 day dosing 
period, with 90%-100% of animals receiving SMT19969 and fidaxomicin surviving 
during the post-dosing follow-up period.",,C. difficile 630,,
352,25652749.txt,Clostridium difficile infection,Hamsters,,,vancomycin,"Whilst protective during treatment, 
onset of mortality was observed on day 11 in animals treated with vancomycin, 
with a 10% survival recorded by day 28.",,C. difficile 630,,
353,25652749.txt,Clostridium difficile infection,Hamsters,,,vancomycin,"Similar results were observed for 
SMT19969 and vancomycin following infection with C. difficile 630, with day 28 
survival rates of 80%-100% and 0%, respectively.",,C. difficile 630,,
354,25652749.txt,Clostridium difficile infection,Hamsters,,,vancomycin,"Fidaxomicin protected animals 
infected with C. difficile 630 from mortality during dosing, although day 28 
survival rates varied from 0% to 40% depending on dose.",,C. difficile 630,,
355,25800047.txt,Clostridium difficile infections,mouse,,,Bacillus amyloliquefaciens,"A significantly lower degree of colon damage was 
detected for B. amyloliquefaciens-treated mice as compared to untreated and S.",C57BL/6,VPI 10463,,
356,25800047.txt,Clostridium difficile infections,mouse,,,Saccharomyces boulardii,"A significantly lower degree of colon damage was 
detected for B. amyloliquefaciens-treated mice as compared to untreated and S.",C57BL/6,VPI 10463,,
357,25805733.txt,Clostridium difficile,mouse,,antibiotic-induced,Av-CD291.2,"Efficacy in a preclinical animal study 
indicates these molecules warrant further development as potential prophylactic 
agents to prevent C. difficile infections in humans.",,,,
358,25805751.txt,,mouse,,antibiotic-associated,"proton 
pump inhibitors (PPIs)","PPI exposure increases the 
severity of intestinal inflammation in mice with C. difficile-associated 
colitis",NF-κB reporter,,,
359,25824219.txt,"Clostridium difficile 
infection",mice,,,Berberine,"Berberine prevented CDIs from relapsing and significantly 
improved survival in the mouse model of CDI.",C57BL/6,,,
360,25824219.txt,"Clostridium difficile 
infection",mice,,,vancomycin,"Berberine prevented CDIs from relapsing and significantly 
improved survival in the mouse model of CDI.",C57BL/6,,,
361,25924765.txt,Clostridium difficile infection,hamster,,,3-MAb combination,"This 3-MAb combination 
protected animals against mortality and also reduced the severity and duration 
of diarrhea associated with challenge with highly virulent strains of C.",,,,
362,25993059.txt,Clostridium difficile,hamster,,,surotomycin,"In 
hamster efficacy studies, surotomycin protected animals at a dose of 0.5 mg/kg, 
PO",,,,
363,2610698.txt,Clostridium difficile,mouse,,,"arginine specific reagent 1,2-cyclohexanedione","Cytotoxicity of both toxins as well as 
mouse lethality of the enterotoxin were drastically decreased as a result of the 
arginine modification",,,,
364,26169276.txt,Recurrent Clostridium difficile infection,mice,,Cefoperazone-treated,vancomycin,"C. difficile counts 
increased within 7 days of completing treatment, accompanied by relapse of 
clinical signs.",,630,,
365,26169276.txt,Recurrent Clostridium difficile infection,mice,,Cefoperazone-treated,"The administration of FMT immediately after vancomycin cleared 
C. difficile and decreased cytotoxicity within 1 week.","C. difficile counts 
increased within 7 days of completing treatment, accompanied by relapse of 
clinical signs.",,630,,
366,26169276.txt,Recurrent Clostridium difficile infection,mice,,Cefoperazone-treated,FMT,"C. difficile counts 
increased within 7 days of completing treatment, accompanied by relapse of 
clinical signs.",,630,,
367,26169403.txt,C. difficile infection (CDI),mice,,antibiotic-induced,"5-(3-(4-fluorophenyl)butyl)-7,8-dimethylpyrido[3,4-b]quinoxaline-1,3(2H,5H)-dione 
(5FDQD)","In C57BL/6 mice, 5FDQD completely 
prevented the onset of lethal antibiotic-induced C. difficile infection (CDI).",C57BL/6,,,
368,26181795.txt,C. difficile,mice,,,"defined diet with 
either 20% protein or 2% protein","C. difficile infected mice fed with defined diets, particularly (and 
unexpectedly) with protein deficient diet, had increased survival, decreased 
weight loss, and decreased overall disease severity.",C57BL/6,VPI10463,,
369,26286574.txt,"Clostridium difficile 
infection",hamster,,,metronidazole,"Accordingly, four leads were more efficacious 
(P < 0.05) than metronidazole in C. difficile-infected animals.",,,,
370,26286574.txt,"Clostridium difficile 
infection",hamster,,,series of metronidazole-bearing tetramic acid substituents,"Accordingly, four leads were more efficacious 
(P < 0.05) than metronidazole in C. difficile-infected animals.",,,,
371,26392484.txt,,mouse,,,"prophage lysin identified from a C. difficile strain, 
CD630, which we named PlyCD",,,,,
372,26400909.txt,Clostridium difficile infection,mouse,,,ebselen,"Treatment in a mouse model of CDI that 
closely resembles the human infection confirmed a therapeutic benefit in the 
form of reduced disease pathology in host tissues that correlated with 
inhibition of the release of the toxic glucosyltransferase domain (GTD).",,,,
373,26461425.txt,Clostridium difficile,mice,,antibiotics,Clostridium difficile CD37,"data show that pre-inoculation of strain CD37 provided mice 
significant protection (survival, p < 0.001 between groups CD37 + UK6 and UK6) 
against subsequent infection with the strain UK6, while mice infected with CD37 
only did not develop any symptoms of C. difficile infection (CDI).",,"UK6 
(BI/NAPI/027)",,
374,26556797.txt,Clostridium difficile infection,mice,,,Epigallocatechin gallate (EGCG),"Furthermore, treatment with EGCG effectively 
protected C. difficile-infected mice from C. difficile-induced death.",,,,
375,26568840.txt,C. difficile infection (CDI),murine,,,combination of vancomycin and metronidazole,"None of the mice in the vancomycin-treated group died during the 
treatment phase compared to a mortality of 17%, 33% and 55% in the combination, 
metronidazole and infected control group, respectively.",C57BL/6J,VPI 10463,,
376,26568840.txt,C. difficile infection (CDI),murine,,,combination of vancomycin and metronidazole,"Mice treated with 
vancomycin alone or in combination with metronidazole recovered from CDI faster 
than mice treated with metronidazole alone.",C57BL/6J,VPI 10463,,
377,26568840.txt,C. difficile infection (CDI),murine,,,combination of vancomycin and metronidazole,"However, after discontinuation of 
treatment, vancomycin-treated and combination-treated mice succumbed to clinical 
and bacteriological relapse.",C57BL/6J,VPI 10463,,
378,26568840.txt,C. difficile infection (CDI),murine,,,vancomycin,"None of the mice in the vancomycin-treated group died during the 
treatment phase compared to a mortality of 17%, 33% and 55% in the combination, 
metronidazole and infected control group, respectively.",C57BL/6J,VPI 10463,,
379,26568840.txt,C. difficile infection (CDI),murine,,,vancomycin,"Mice treated with 
vancomycin alone or in combination with metronidazole recovered from CDI faster 
than mice treated with metronidazole alone.",C57BL/6J,VPI 10463,,
380,26568840.txt,C. difficile infection (CDI),murine,,,vancomycin,"However, after discontinuation of 
treatment, vancomycin-treated and combination-treated mice succumbed to clinical 
and bacteriological relapse.",C57BL/6J,VPI 10463,,
381,26568840.txt,C. difficile infection (CDI),murine,,,metronidazole,"None of the mice in the vancomycin-treated group died during the 
treatment phase compared to a mortality of 17%, 33% and 55% in the combination, 
metronidazole and infected control group, respectively.",C57BL/6J,VPI 10463,,
382,26568840.txt,C. difficile infection (CDI),murine,,,metronidazole,"Mice treated with 
vancomycin alone or in combination with metronidazole recovered from CDI faster 
than mice treated with metronidazole alone.",C57BL/6J,VPI 10463,,
383,26568840.txt,C. difficile infection (CDI),murine,,,metronidazole,"However, after discontinuation of 
treatment, vancomycin-treated and combination-treated mice succumbed to clinical 
and bacteriological relapse.",C57BL/6J,VPI 10463,,
384,26573738.txt,Clostridium difficile,hamster,,,"combination of 
two strains of engineered L. paracasei BL23","Half of the hamsters in the treated 
group survived until the termination of the experiment at day 5 and showed 
either no damage or limited inflammation of the colonic mucosa despite having 
been colonized with C. difficile for up to 4 days.",,,,
385,26643348.txt,Clostridium difficile infection,hamster,,,Bacteriophage (phage) therapy,"Using a hamster model, the oral delivery of optimized phage combinations 
resulted in reduced C. difficile colonization at 36 h postinfection.",,,,
386,26643348.txt,Clostridium difficile infection,hamster,,,Bacteriophage (phage) therapy,"In a 
challenge model of the disease, phage treatment delayed the onset of symptoms by 
33 h compared to the time of onset of symptoms in untreated animals.",,,,
387,26655716.txt,Clostridium difficile,mouse,,,"insect 
peptide CopA3","Moreover, CopA3 treatment 
ameliorated Clostridium difficile toxin As-induced inflammation responses in the 
mouse small intestine (acute enteritis) and completely blocked inflammatory 
responses and subsequent lethality in the dextran sulfate sodium-induced mouse 
model of chronic colitis.",,,,
388,26809801.txt,Clostridium difficile,mouse,,toxin A-induced,potassium acetate,"In addition, PA treatment 
significantly decreased the production of IL-6 (a marker of inflamed tissue) in 
the toxin A-induced mouse enteritis model.",,,,
389,26832756.txt,Clostridium difficile infection,mice,,antibiotics,SQ641,"Five day treatment of CDI with SQ641 resulted in higher 14 day survival 
rates in mice compared with either vancomycin or vehicle alone.",C57BL/6,VPI10463,,
390,26832756.txt,Clostridium difficile infection,mice,,antibiotics,vancomycin,"Five day treatment of CDI with SQ641 resulted in higher 14 day survival 
rates in mice compared with either vancomycin or vehicle alone.",C57BL/6,VPI10463,,
391,26917573.txt,Clostridium difficile infection,mice,,antibiotics,Vancomycin,"Levels of disease severity, relapse, and mortality were increased, and 
recovery from infection was slower in aged mice compared to young mice.","Young (age, 2 months) and aged (age, 18 months) C57BL/6",VPI 10463,,
392,27067323.txt,Clostridium difficile infections,murine,,,trifluoperazine (TFP),"In both models, TFP treatment resulted in 
increased survivability of infected animals.",,,,
393,27143131.txt,Clostridium difficile,hamster,,,Kibdelomycin,"It is highly efficacious 
in the hamster model of C. difficile infection providing 100% protection at 
>6mg/kg and 80% protection at 1.56mg/kg by oral dosing without systemic 
exposure.",,,,
394,27180007.txt,Clostridium difficile infection,murine,,,kefir,"We employed a murine CDI 
model to study the probiotic protective mechanisms and unexpectedly determined 
that kefir drastically increased disease severity.",,,,
395,27189122.txt,Clostridium difficile,hamsters,,,Ramizol,"We 
show this non-systemic nature of the antibiotic translates to over 70% survival 
of hamsters in a Clostridium difficile colitis model.",,,,
396,27262694.txt,Clostridium difficile.,dogs,,,SYN-004,"In animal 
studies, SYN-004 degraded ceftriaxone in the GI tract of dogs and protected the 
microbiome of pigs from ceftriaxone-induced changes.",,,,
397,27262694.txt,Clostridium difficile.,pigs,,,SYN-004,"In animal 
studies, SYN-004 degraded ceftriaxone in the GI tract of dogs and protected the 
microbiome of pigs from ceftriaxone-induced changes.",,,,
398,27280500.txt,Clostridium difficile infection,mice,,,indole-3-carbinol (I3C),"B6 mice fed an AHR ligand-deficient, semipurified diet have 
significantly increased disease severity (P<0.001) and mortality (P < 0.001) 
compared with mice fed on diet containing I3C.",C57BL/6,,,
399,27280500.txt,Clostridium difficile infection,mice,,,indole-3-carbinol (I3C),"The addition of I3C to the diet 
of AHR null mice had less of an impact than in AHR heterozygous littermates, 
although some protection was seen.",C57BL/6,,,
400,27280500.txt,Clostridium difficile infection,mice,,,indole-3-carbinol (I3C),"B6 mice fed an AHR ligand-deficient, semipurified diet have 
significantly increased disease severity (P<0.001) and mortality (P < 0.001) 
compared with mice fed on diet containing I3C.",AHR,,,
401,27280500.txt,Clostridium difficile infection,mice,,,indole-3-carbinol (I3C),"The addition of I3C to the diet 
of AHR null mice had less of an impact than in AHR heterozygous littermates, 
although some protection was seen.",AHR,,,
402,27280500.txt,Clostridium difficile infection,mice,,,indole-3-carbinol (I3C),"B6 mice fed an AHR ligand-deficient, semipurified diet have 
significantly increased disease severity (P<0.001) and mortality (P < 0.001) 
compared with mice fed on diet containing I3C.",AHR null,,,
403,27280500.txt,Clostridium difficile infection,mice,,,indole-3-carbinol (I3C),"The addition of I3C to the diet 
of AHR null mice had less of an impact than in AHR heterozygous littermates, 
although some protection was seen.",AHR null,,,
404,27336843.txt,Clostridium difficile (C. difficile) infection,hamster,,"toxin challenge 
model",anti-TcdA (CANmAbA4),"The humanized anti-TcdA (CANmAbA4) and anti-TcdB 
(CANmAbB4 and CANmAbB1) antibodies showed broad spectrum in vitro neutralization 
of toxins from clinical strains and neutralization in a mouse toxin challenge 
model.",,,,
405,27336843.txt,Clostridium difficile (C. difficile) infection,hamster,,"toxin challenge 
model","anti-TcdB 
(CANmAbB4 and CANmAbB1)","The humanized anti-TcdA (CANmAbA4) and anti-TcdB 
(CANmAbB4 and CANmAbB1) antibodies showed broad spectrum in vitro neutralization 
of toxins from clinical strains and neutralization in a mouse toxin challenge 
model.",,,,
406,27336843.txt,Clostridium difficile (C. difficile) infection,hamster,,"toxin challenge 
model",anti-TcdA (CANmAbA4),"Moreover, co-administration of humanized antibodies (CANmAbA4 and 
CANmAbB4 cocktail) provided a high level of protection in a dose dependent 
manner (85% versus 57% survival at day 22 for 50 mg/kg and 20 mg/kg doses, 
respectively) in a hamster gastrointestinal infection (GI) model.",,,,
407,27336843.txt,Clostridium difficile (C. difficile) infection,hamster,,"toxin challenge 
model","anti-TcdB 
(CANmAbB4 and CANmAbB1)","Moreover, co-administration of humanized antibodies (CANmAbA4 and 
CANmAbB4 cocktail) provided a high level of protection in a dose dependent 
manner (85% versus 57% survival at day 22 for 50 mg/kg and 20 mg/kg doses, 
respectively) in a hamster gastrointestinal infection (GI) model.",,,,
408,27336843.txt,Clostridium difficile (C. difficile) infection,mouse,,"toxin challenge 
model",anti-TcdA (CANmAbA4),"The humanized anti-TcdA (CANmAbA4) and anti-TcdB 
(CANmAbB4 and CANmAbB1) antibodies showed broad spectrum in vitro neutralization 
of toxins from clinical strains and neutralization in a mouse toxin challenge 
model.",,,,
409,27336843.txt,Clostridium difficile (C. difficile) infection,mouse,,"toxin challenge 
model","anti-TcdB 
(CANmAbB4 and CANmAbB1)","The humanized anti-TcdA (CANmAbA4) and anti-TcdB 
(CANmAbB4 and CANmAbB1) antibodies showed broad spectrum in vitro neutralization 
of toxins from clinical strains and neutralization in a mouse toxin challenge 
model.",,,,
410,27336843.txt,Clostridium difficile (C. difficile) infection,mouse,,"toxin challenge 
model",anti-TcdA (CANmAbA4),"Moreover, co-administration of humanized antibodies (CANmAbA4 and 
CANmAbB4 cocktail) provided a high level of protection in a dose dependent 
manner (85% versus 57% survival at day 22 for 50 mg/kg and 20 mg/kg doses, 
respectively) in a hamster gastrointestinal infection (GI) model.",,,,
411,27336843.txt,Clostridium difficile (C. difficile) infection,mouse,,"toxin challenge 
model","anti-TcdB 
(CANmAbB4 and CANmAbB1)","Moreover, co-administration of humanized antibodies (CANmAbA4 and 
CANmAbB4 cocktail) provided a high level of protection in a dose dependent 
manner (85% versus 57% survival at day 22 for 50 mg/kg and 20 mg/kg doses, 
respectively) in a hamster gastrointestinal infection (GI) model.",,,,
412,27413067.txt,Clostridium difficile infection,piglets,,,VNA2-Tcd,"When given systemically by parenteral 
administration, VNA2-Tcd protected against CDI in gnotobiotic piglets and mice 
and to a lesser extent in hamsters.",gnotobiotic,,,
413,27413067.txt,Clostridium difficile infection,mice,,,VNA2-Tcd,"When given systemically by parenteral 
administration, VNA2-Tcd protected against CDI in gnotobiotic piglets and mice 
and to a lesser extent in hamsters.",gnotobiotic,,,
414,27413067.txt,Clostridium difficile infection,hamsters,,,VNA2-Tcd,"When given systemically by parenteral 
administration, VNA2-Tcd protected against CDI in gnotobiotic piglets and mice 
and to a lesser extent in hamsters.",gnotobiotic,,,
415,27514478.txt,C. difficile infection (CDI),hamster,,,Saccharomyces boulardii CNCM I-745 (S.b),"Oral gavage of live, 
but not heated, S.b starting 5 days before C. difficile infection significantly 
reduced cecal tissue damage, NF-κB phosphorylation, and TNFα protein expression 
caused by infection with all strains.",,VPI10463,,
416,27514478.txt,C. difficile infection (CDI),hamster,,,Saccharomyces boulardii CNCM I-745 (S.b),"Oral gavage of live, 
but not heated, S.b starting 5 days before C. difficile infection significantly 
reduced cecal tissue damage, NF-κB phosphorylation, and TNFα protein expression 
caused by infection with all strains.",,"outbreak-associated strains 
ribotype 017, 027, and 078",,
417,27527088.txt,Clostridium difficile,mice,,,vancomycin,"Treatment with vancomycin prevents disease 
initially by inhibiting outgrowth of C. difficile but also delays microbiota 
recovery, leading to disease relapse following discontinuation of therapy.",,,,
418,27527088.txt,Clostridium difficile,mice,,,vancomycin,"In 
contrast, actoxumab/bezlotoxumab treatment does not impact the C. difficile 
burden but rather prevents the appearance of toxin-dependent symptoms during the 
early severe phase of disease, effectively preventing disease until the 
microbiota (the body's natural defense against C. difficile) has fully 
recovered.",,,,
419,27527088.txt,Clostridium difficile,hamsters,,,vancomycin,"Treatment with vancomycin prevents disease 
initially by inhibiting outgrowth of C. difficile but also delays microbiota 
recovery, leading to disease relapse following discontinuation of therapy.",,,,
420,27527088.txt,Clostridium difficile,hamsters,,,vancomycin,"In 
contrast, actoxumab/bezlotoxumab treatment does not impact the C. difficile 
burden but rather prevents the appearance of toxin-dependent symptoms during the 
early severe phase of disease, effectively preventing disease until the 
microbiota (the body's natural defense against C. difficile) has fully 
recovered.",,,,
421,27527088.txt,Clostridium difficile,mice,,,actoxumab/bezlotoxumab,"Treatment with vancomycin prevents disease 
initially by inhibiting outgrowth of C. difficile but also delays microbiota 
recovery, leading to disease relapse following discontinuation of therapy.",,,,
422,27527088.txt,Clostridium difficile,mice,,,actoxumab/bezlotoxumab,"In 
contrast, actoxumab/bezlotoxumab treatment does not impact the C. difficile 
burden but rather prevents the appearance of toxin-dependent symptoms during the 
early severe phase of disease, effectively preventing disease until the 
microbiota (the body's natural defense against C. difficile) has fully 
recovered.",,,,
423,27527088.txt,Clostridium difficile,hamsters,,,actoxumab/bezlotoxumab,"Treatment with vancomycin prevents disease 
initially by inhibiting outgrowth of C. difficile but also delays microbiota 
recovery, leading to disease relapse following discontinuation of therapy.",,,,
424,27527088.txt,Clostridium difficile,hamsters,,,actoxumab/bezlotoxumab,"In 
contrast, actoxumab/bezlotoxumab treatment does not impact the C. difficile 
burden but rather prevents the appearance of toxin-dependent symptoms during the 
early severe phase of disease, effectively preventing disease until the 
microbiota (the body's natural defense against C. difficile) has fully 
recovered.",,,,
425,27573235.txt,Clostridium difficile-associated diarrhea,mice,,,Lactobacillus rhamnosus L34,"Interestingly, a specific 
dose of Lactobacillus rhamnosus L34 attenuated CDAD and decreased serum BG and 
FITC-dextran, but not other parameters.",,,,
426,27707993.txt,Clostridium difficile,mice,,,vancomycin,"During vancomycin treatment, mice were highly 
susceptible to intestinal colonization by an antibiotic-resistant pathogen and, 
upon antibiotic cessation, a less-resilient microbiota allowed higher levels of 
pathogen colonization.",,,,
427,27999606.txt,Clostridium difficile associated diarrhea,mouse,,exposure to antimicrobial mixture.,Traditional Chinese medicine QPYF,"The survival rate of QPYF group (93.75%) was 
higher than that of model control group (65%).",C57BL/6,VPI 10463,,
428,28173695.txt,Clostridium difficile,mouse,,,"Periplanetasin-2 (Peri-2, YPCKLNLKLGKVPFH)","Peri-2 blocked the mucosal disruption and inflammatory response 
caused by toxin A.",,,,
429,28217763.txt,Clostridium difficile infection,mice,,,tigecycline,"Tigecycline, linezolid, and ceftriaxone caused transient disruption 
of colonization resistance to C. difficile, whereas piperacillin/tazobactam 
caused disruption that persisted for 7 days post-treatment.",,,,
430,28217763.txt,Clostridium difficile infection,mice,,,ceftriaxone,"Tigecycline, linezolid, and ceftriaxone caused transient disruption 
of colonization resistance to C. difficile, whereas piperacillin/tazobactam 
caused disruption that persisted for 7 days post-treatment.",,,,
431,28217763.txt,Clostridium difficile infection,mice,,,piperacillin-tazobactam,"Tigecycline, linezolid, and ceftriaxone caused transient disruption 
of colonization resistance to C. difficile, whereas piperacillin/tazobactam 
caused disruption that persisted for 7 days post-treatment.",,,,
432,28217763.txt,Clostridium difficile infection,mice,,,linezolid,"Tigecycline, linezolid, and ceftriaxone caused transient disruption 
of colonization resistance to C. difficile, whereas piperacillin/tazobactam 
caused disruption that persisted for 7 days post-treatment.",,,,
433,28453386.txt,Clostridium difficile infection,mouse,,,Vancomycin,"Vancomycin, an anti-C. difficile 
antibiotic, led to similar changes in antibody response, suggesting a connection 
between microbiome and antibody response in the context of aging, which would 
require a much more nuanced look at the treatment of CDI.",,,,
434,28484429.txt,,mouse,,antibiotic,carvacrol,"Carvacrol supplementation significantly reduced the incidence of 
diarrhea and improved the clinical and diarrhea scores in mice (p < 0.05).",C57BL/6,ATCC 1870,,
435,28497217.txt,Clostridium difficile,mice,,,viable mixture of these three strains (109 CFU/mL),"The results obtained from histological 
analysis confirmed the effectiveness of our three potential probiotic strains 
which expressed inhibition of C. difficile and maintained the structural 
integrity of the liver and intestinal cells.",,,,
436,28580440.txt,Clostridium difficile,mice,,,"Enterococcus 
faecium","Ectopic expression of SagA in non-protective and 
probiotic bacteria is sufficient to enhance intestinal barrier function and 
confer resistance",,,,
437,28584146.txt,Clostridium difficile,mouse,,,Aztreonam,"Aztreonam did not affect colonization resistance, whereas 
piperacillin-tazobactam disrupted colonization resistance 3 days after 
piperacillin-tazobactam treatment, with complete recovery by 11 days after 
treatment.",,,,
438,28584146.txt,Clostridium difficile,mouse,,,piperacillin-tazobactam,"Aztreonam did not affect colonization resistance, whereas 
piperacillin-tazobactam disrupted colonization resistance 3 days after 
piperacillin-tazobactam treatment, with complete recovery by 11 days after 
treatment.",,,,
439,28623367.txt,C. difficile,mice,,,hyperimmune bovine colostrum (HBC),"Administration of TcdB-specific colostrum alone, or in combination 
with spore or vegetative cell-targeted colostrum, prevents and treats C.",,,,
440,28739791.txt,Clostridium difficile infection.,hamster,,,DAV131A,"All hamsters that received no DAV131A 
died, but none of those that received 1,800 mg/kg/day died.",,,,
441,28739791.txt,Clostridium difficile infection.,hamster,,,moxifloxacin,"All hamsters that received no DAV131A 
died, but none of those that received 1,800 mg/kg/day died.",,,,
442,28747822.txt,Clostridium difficile infection,mouse,,,Bifidobacterium longum ATCC 15707,"The 
survival rates for mice given the pathogen alone, and with live cells, or dead 
cells of B. longum were 40, 70, and 60%, respectively.",,. difficile 027,,
443,28761936.txt,Clostridium difficile infection,mice,,,,"we demonstrated that C. difficile highly colonized ceca of mice 
pretreated with any of three antibiotics from distinct classes.",,,,
444,28764868.txt,C. difficile,mouse,,,lanthionine synthetase C-like 2 (LANCL2),"We further validate the potential of LANCL2 pathway 
activation, in a mouse model of C. difficile infection in which it displays an 
ability to decrease weight loss and inflammatory cell types while protecting 
against mortality.",,,,
445,28801119.txt,C. difficile infection,murine,,,fecal microbiota transplantation,"Mice treated with frozen 
(n = 5/group), lyophilized (n = 5/group) products stored for ≤ 7-month or fresh 
FMT product (n = 22) were protected from post C. difficile challenge diarrhea.",,,,
446,28811642.txt,C. difficile,mice,,,Fe3-δO4 nanoparticles.,"In a C. difficile infection animal model, the 
inflammatory level triple decreased in mice with colonic C. difficile spores 
treated with Fe3-δO4 nanoparticles.",,,,
447,28856119.txt,C. difficile,mouse,,initiation,,"Administration of 
anti-spore IgY to C57BL/6 mice prior and during CDI delayed the appearance of 
the diarrhea by 1.5 day, and spore adherence to the colonic mucosa by 90%.",C57BL/6,,,
448,28856119.txt,C. difficile,mouse,,initiation,,"Notably, in the recurrence model, co-administration of anti-spore IgY coupled 
with vancomycin delayed the appearance of recurrent diarrhea by a median of 2 
days.",C57BL/6,,,
449,28856119.txt,C. difficile,mouse,,recurrence,,"Administration of 
anti-spore IgY to C57BL/6 mice prior and during CDI delayed the appearance of 
the diarrhea by 1.5 day, and spore adherence to the colonic mucosa by 90%.",C57BL/6,,,
450,28856119.txt,C. difficile,mouse,,recurrence,,"Notably, in the recurrence model, co-administration of anti-spore IgY coupled 
with vancomycin delayed the appearance of recurrent diarrhea by a median of 2 
days.",C57BL/6,,,
451,28949065.txt,,mouse,,toxin A-induced,"Periplanetasin-4 
(Peri-4),","Peri-4 also 
ameliorated the severe inflammatory responses seen in the toxin A-induced mouse 
enteritis model, rescuing the villus disruption and interleukin-6 production 
induced by luminal injection of",,,,
452,29109161.txt,Clostridium difficile infection,mice,,,trifluoperazine,"Likewise, when they were used in combination with 
vancomycin, all three drugs provided mice with 80 to 100% protection from fatal 
oral Clostridium difficile infection when they were administered at 24 h 
postinfection.",,,,
453,29109161.txt,Clostridium difficile infection,mice,,,amoxapine,"Likewise, when they were used in combination with 
vancomycin, all three drugs provided mice with 80 to 100% protection from fatal 
oral Clostridium difficile infection when they were administered at 24 h 
postinfection.",,,,
454,29109161.txt,Clostridium difficile infection,mice,,,doxapram,"Likewise, when they were used in combination with 
vancomycin, all three drugs provided mice with 80 to 100% protection from fatal 
oral Clostridium difficile infection when they were administered at 24 h 
postinfection.",,,,
455,29109161.txt,Clostridium difficile infection,mice,,,vancomycin,"Likewise, when they were used in combination with 
vancomycin, all three drugs provided mice with 80 to 100% protection from fatal 
oral Clostridium difficile infection when they were administered at 24 h 
postinfection.",,,,
456,29140433.txt,C. difficile,mice,,,interleukin-27 (IL-27),"IL-27 administration reduced CDI-associated mortality and 
tissue pathology with improved C. difficile clearance in WT mice",,,,
457,29140433.txt,C. difficile,mice,,,WT,"IL-27 administration reduced CDI-associated mortality and 
tissue pathology with improved C. difficile clearance in WT mice",,,,
458,29360463.txt,Clostridium difficile,mice,,,"cationic steroid 
antimicrobial 13 (CSA13)","CDI of mice caused 60% mortality, significant bodyweight loss, and 
colonic damage 3 days after infection; these events were prevented by 
subcutaneous injection of CSA13 or oral administration CSA13-Eudragit.",C57BL/6J,,,
459,29360463.txt,Clostridium difficile,mice,,,CSA13-Eudragit,"CDI of mice caused 60% mortality, significant bodyweight loss, and 
colonic damage 3 days after infection; these events were prevented by 
subcutaneous injection of CSA13 or oral administration CSA13-Eudragit.",C57BL/6J,,,
460,29360463.txt,Clostridium difficile,mice,,,vancomycin,"CDI of mice caused 60% mortality, significant bodyweight loss, and 
colonic damage 3 days after infection; these events were prevented by 
subcutaneous injection of CSA13 or oral administration CSA13-Eudragit.",C57BL/6J,,,
461,29385239.txt,Clostridium difficile (,Mice,,clindamycin,Faecalibacterium prausnitzii (FP),"Although all mice exhibited bacterial overgrowth and CD colonization, 
bacterial burden resolved quicker in the FP + prebiotic group.",,,,
462,29385239.txt,Clostridium difficile (,Mice,,clindamycin,prebiotic,"Although all mice exhibited bacterial overgrowth and CD colonization, 
bacterial burden resolved quicker in the FP + prebiotic group.",,,,
463,29439962.txt,Clostridium difficile infection,hamster,,,DS-2969b,"In a hamster 
CDI model, 5-day oral administration of DS-2969b conferred complete protection 
from recurrence and mortality at 0.3 mg/kg of body weight once a day, in 
contrast to a 50% survival rate with fidaxomicin at 3 mg/kg once a day and 0% 
with vancomycin at a 50-mg/kg/dose twice a day.",,,,
464,29439962.txt,Clostridium difficile infection,hamster,,,fidaxomicin,"In a hamster 
CDI model, 5-day oral administration of DS-2969b conferred complete protection 
from recurrence and mortality at 0.3 mg/kg of body weight once a day, in 
contrast to a 50% survival rate with fidaxomicin at 3 mg/kg once a day and 0% 
with vancomycin at a 50-mg/kg/dose twice a day.",,,,
465,29439962.txt,Clostridium difficile infection,hamster,,,vancomycin,"In a hamster 
CDI model, 5-day oral administration of DS-2969b conferred complete protection 
from recurrence and mortality at 0.3 mg/kg of body weight once a day, in 
contrast to a 50% survival rate with fidaxomicin at 3 mg/kg once a day and 0% 
with vancomycin at a 50-mg/kg/dose twice a day.",,,,
466,29463537.txt,Clostridium difficile infection,murine,,,fidaxomicin,"All 
fidaxomicin-exposed mice (except for one at day 8) were resistant to C.",,,,
467,29463537.txt,Clostridium difficile infection,murine,,,fidaxomicin,"9 of 15 vancomycin-exposed mice were 
susceptible to C. difficile colonization until day 12.",,,,
468,29463537.txt,Clostridium difficile infection,murine,,,vancomycin,"All 
fidaxomicin-exposed mice (except for one at day 8) were resistant to C.",,,,
469,29463537.txt,Clostridium difficile infection,murine,,,vancomycin,"9 of 15 vancomycin-exposed mice were 
susceptible to C. difficile colonization until day 12.",,,,
470,29483125.txt,Clostridium difficile infection,murine,,toxin challenge model,small-molecule inhibitor (VB-82252),"Oral dosing of the inhibitor prevented inflammation in a murine intrarectal 
toxin challenge model.",,,,
471,29483125.txt,Clostridium difficile infection,murine,,toxin challenge model,small-molecule inhibitor (VB-82252),"In a murine model of recurrent CDI, the inhibitor reduced 
weight loss and gut inflammation during acute disease and did not cause the 
recurrent disease that was observed with vancomycin treatment.",,,,
472,29483125.txt,Clostridium difficile infection,murine,,toxin challenge model,vancomycin,"Oral dosing of the inhibitor prevented inflammation in a murine intrarectal 
toxin challenge model.",,,,
473,29483125.txt,Clostridium difficile infection,murine,,toxin challenge model,vancomycin,"In a murine model of recurrent CDI, the inhibitor reduced 
weight loss and gut inflammation during acute disease and did not cause the 
recurrent disease that was observed with vancomycin treatment.",,,,
474,29530853.txt,Clostridium difficile infections,mouse,,,"vancomycin 
daily for 10 days","Vancomycin taper-treated mice developed 
alterations of the microbiota and disruption of colonization resistance that was 
persistent 18 days after treatment.",,,,
475,29530853.txt,Clostridium difficile infections,mouse,,,"vancomycin 
daily for 10 days","In contrast, mice treated with a 10-day 
course of vancomycin exhibited recovery of the microbiota and of colonization 
resistance by 15 days after treatment, and fidaxomicin-treated mice maintained 
intact colonization resistance.",,,,
476,29530853.txt,Clostridium difficile infections,mouse,,,vancomycin in a tapering dose for 42 days,"Vancomycin taper-treated mice developed 
alterations of the microbiota and disruption of colonization resistance that was 
persistent 18 days after treatment.",,,,
477,29530853.txt,Clostridium difficile infections,mouse,,,vancomycin in a tapering dose for 42 days,"In contrast, mice treated with a 10-day 
course of vancomycin exhibited recovery of the microbiota and of colonization 
resistance by 15 days after treatment, and fidaxomicin-treated mice maintained 
intact colonization resistance.",,,,
478,29530853.txt,Clostridium difficile infections,mouse,,,fidaxomicin,"Vancomycin taper-treated mice developed 
alterations of the microbiota and disruption of colonization resistance that was 
persistent 18 days after treatment.",,,,
479,29530853.txt,Clostridium difficile infections,mouse,,,fidaxomicin,"In contrast, mice treated with a 10-day 
course of vancomycin exhibited recovery of the microbiota and of colonization 
resistance by 15 days after treatment, and fidaxomicin-treated mice maintained 
intact colonization resistance.",,,,
480,29615987.txt,C. difficile,hamster,,,OG253,"OG253 ultimately emerged as the lead compound 
based on superior in vivo efficacy along with an apparent lack of relapse in a 
hamster model of infection.",,,,
481,29667487.txt,C. difficile infection (CDI),murine,,,Candida albicans,"The results reported here demonstrate that colonization with 
the human commensal fungus Candida albicans protects against lethal CDI in a 
murine model.",,,,
482,29667487.txt,C. difficile infection (CDI),murine,,,Candida albicans,"The results reported here demonstrate that colonization with 
the human commensal fungus Candida albicans protects against lethal CDI in a 
murine model.",,,,
483,29667487.txt,C. difficile infection (CDI),murine,,,IL-17A,"The results reported here demonstrate that colonization with 
the human commensal fungus Candida albicans protects against lethal CDI in a 
murine model.",,,,
484,29667487.txt,C. difficile infection (CDI),murine,,,IL-17A,"The results reported here demonstrate that colonization with 
the human commensal fungus Candida albicans protects against lethal CDI in a 
murine model.",,,,
485,29667487.txt,C. difficile infection (CDI),murine,,,Candida albicans,"Administration of cytokine IL-17A was demonstrated to be 
protective against lethal murine CDI in mice not colonized with C. albicans.",,,,
486,29667487.txt,C. difficile infection (CDI),murine,,,Candida albicans,"Administration of cytokine IL-17A was demonstrated to be 
protective against lethal murine CDI in mice not colonized with C. albicans.",,,,
487,29667487.txt,C. difficile infection (CDI),murine,,,IL-17A,"Administration of cytokine IL-17A was demonstrated to be 
protective against lethal murine CDI in mice not colonized with C. albicans.",,,,
488,29667487.txt,C. difficile infection (CDI),murine,,,IL-17A,"Administration of cytokine IL-17A was demonstrated to be 
protective against lethal murine CDI in mice not colonized with C. albicans.",,,,
489,29686297.txt,Clostridium difficile,mice,,antibiotic-induced,"diet containing a 
complex mixture of MACs","We show that C. difficile 
burdens are suppressed through the addition of either a diet containing a 
complex mixture of MACs or a simplified diet containing inulin as the sole MAC 
source.",,,,
490,29686297.txt,Clostridium difficile,mice,,antibiotic-induced,simplified diet containing inulin,"We show that C. difficile 
burdens are suppressed through the addition of either a diet containing a 
complex mixture of MACs or a simplified diet containing inulin as the sole MAC 
source.",,,,
491,29768720.txt,Clostridium difficile infection,mouse,,,bis-cyclic guanidine compounds,"Moreover, the most selective compound is also effective in the 
treatment of C. difficile-induced disease in a mouse model of CDI",,,,
492,29894469.txt,C. difficile infection (CDI),hamster,,,OG716,"In vivo 
testing ultimately identified OG716 as the lead compound, which conferred 100% 
survival and no relapse at 3 weeks post infection.",Golden Syrian,,,
493,29950381.txt,Clostridium difficile infection,mouse,,antibiotic,,"As distinct antibiotics are 
associated with different risk levels for CDI, we utilized a mouse model of 
infection with 3 separate antibiotic pretreatment regimens to generate 
alternative gut microbiomes that each allowed for C. difficile colonization but 
varied in clearance rate.",,,,
494,29967595.txt,C. difficile infection (CDI),hamsters,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Syrian Golden,VPI10463,,
495,29967595.txt,C. difficile infection (CDI),hamsters,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Syrian Golden,VPI10463,,
496,29967595.txt,C. difficile infection (CDI),hamsters,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Syrian Golden,KY34,,
497,29967595.txt,C. difficile infection (CDI),hamsters,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Syrian Golden,KY34,,
498,29967595.txt,C. difficile infection (CDI),hamsters,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Syrian Golden,VPI10463,,
499,29967595.txt,C. difficile infection (CDI),hamsters,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Syrian Golden,VPI10463,,
500,29967595.txt,C. difficile infection (CDI),hamsters,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Syrian Golden,KY34,,
501,29967595.txt,C. difficile infection (CDI),hamsters,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Syrian Golden,KY34,,
502,29967595.txt,C. difficile infection (CDI),rats,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Syrian Golden,VPI10463,,
503,29967595.txt,C. difficile infection (CDI),rats,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Syrian Golden,VPI10463,,
504,29967595.txt,C. difficile infection (CDI),rats,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Syrian Golden,KY34,,
505,29967595.txt,C. difficile infection (CDI),rats,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Syrian Golden,KY34,,
506,29967595.txt,C. difficile infection (CDI),rats,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Syrian Golden,VPI10463,,
507,29967595.txt,C. difficile infection (CDI),rats,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Syrian Golden,VPI10463,,
508,29967595.txt,C. difficile infection (CDI),rats,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Syrian Golden,KY34,,
509,29967595.txt,C. difficile infection (CDI),rats,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Syrian Golden,KY34,,
510,29967595.txt,C. difficile infection (CDI),hamsters,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Wistar,VPI10463,,
511,29967595.txt,C. difficile infection (CDI),hamsters,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Wistar,VPI10463,,
512,29967595.txt,C. difficile infection (CDI),hamsters,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Wistar,KY34,,
513,29967595.txt,C. difficile infection (CDI),hamsters,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Wistar,KY34,,
514,29967595.txt,C. difficile infection (CDI),hamsters,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Wistar,VPI10463,,
515,29967595.txt,C. difficile infection (CDI),hamsters,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Wistar,VPI10463,,
516,29967595.txt,C. difficile infection (CDI),hamsters,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Wistar,KY34,,
517,29967595.txt,C. difficile infection (CDI),hamsters,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Wistar,KY34,,
518,29967595.txt,C. difficile infection (CDI),rats,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Wistar,VPI10463,,
519,29967595.txt,C. difficile infection (CDI),rats,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Wistar,VPI10463,,
520,29967595.txt,C. difficile infection (CDI),rats,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Wistar,KY34,,
521,29967595.txt,C. difficile infection (CDI),rats,,clindamycin phosphate,"Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Wistar,KY34,,
522,29967595.txt,C. difficile infection (CDI),rats,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Wistar,VPI10463,,
523,29967595.txt,C. difficile infection (CDI),rats,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Wistar,VPI10463,,
524,29967595.txt,C. difficile infection (CDI),rats,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","More than 70% of hamsters orally infected with C. difficile died 
without exhibiting diarrhea regardless of toxigenicity of strain.",Wistar,KY34,,
525,29967595.txt,C. difficile infection (CDI),rats,,"received 10% egg white dissolved in 
drinking water for 1 week ad libitum following intramuscular administration of 
200 mg/kg MNZ twice a day for 3 days","Clostridium butyricum MIYAIRI 588 
(CBM)","The incidence 
of diarrhea was significantly decreased in C. butyricum treated rats.",Wistar,KY34,,
526,29998951.txt,Clostridium difficile (,hamster,,,Bezlotoxumab,"The 
antibody prolonged survival time of hamster and rat CDI models in a 
dose-dependent manner.",,,,
527,29998951.txt,Clostridium difficile (,rat,,,Bezlotoxumab,"The 
antibody prolonged survival time of hamster and rat CDI models in a 
dose-dependent manner.",,,,
528,30012758.txt,Clostridium difficile infection,hamster,,,CamSA,"Treatment of C. difficile-challenged hamsters with 
CamSA doubled the mean time to death, compared to control hamsters.",,,,
529,30012758.txt,Clostridium difficile infection,hamster,,,CamSA,"Protected animals remained disease-free at least 30 days 
postchallenge and showed no signs of colonic tissue damage.",,,,
530,30238771.txt,Clostridium difficile infection,mouse,,,indomethacin,"These results demonstrate a negative impact of nonsteroidal 
anti-inflammatory drugs on antibiotic-associated CDI in mice",,,,
531,30292822.txt,Clostridioides difficile infection,piglets,,,"Z31, a NTCD strain","All evaluated parameters were significantly lower in 
animals that received Z31 compared to the positive control.",,,,
532,30356740.txt,Clostridium difficile infection,mouse,,antibiotics,Pediococcus pentosaceus LI05,"The oral administration of P. pentosaceus LI05 improved the 
survival rate and alleviated the histopathological impact of C. difficile.",C57BL/6,,,VPI10463
533,30392779.txt,Clostridium difficile infection.,hamster,,,11d,"efficacious in a 
hamster survival model of Clostridium difficile infection.",,,,
534,30482680.txt,Clostridium difficile,mouse,,,inositol hexakisphosphate (IP6),"We found that oral 
administration of IP6 analogs attenuated inflammation and promoted survival in 
mouse models of CDI.",,,,
535,30524414.txt,"Clostridium 
difficile.",hamsters,,antibiotics,Ursodeoxycholic acid (UDCA),"in our hamster model, UDCA 
was inefficient to prevent CDI, despite high levels of UDCA in feces.",,,,
536,30531960.txt,Clostridium difficile,mice,,,niclosamide,"niclosamide reduced both primary disease 
and recurrence, without disrupting the diversity or composition of the gut 
microbiota.",,,,
537,30619112.txt,Clostridium difficile,mouse,,,B. fragilis strain ZY-312,"CDI 
model mice prophylactically treated with B. fragilis exhibited significantly 
higher survival rates (100% in low dosage group, 87.5% in high dosage group) and 
improved clinical manifestations.",,,,
538,30622186.txt,Clostridium difficile infection,mouse,,,indomethacin,"brief NSAID exposure 
prior to CDI increases the severity of the infectious colitis",,,,
539,30645630.txt,Clostridium difficile infection,mouse,,antibiotics,C. albicans,"C. albicans administration enhanced the 
severity of the C. difficile infection model as determined by mortality rate, 
weight loss, gut leakage (FITC-dextran assay), and serum and intestinal tissue 
cytokines.",,,,
540,30687250.txt,C. difficile infection (CDI),mouse,,,"designated LHD, is composed of two 
parts connected by a 3-repeating unit linker ""(GGGGS)3"": the catalytic domain of 
a lysin protein from a C. difficile bacteriophage phiC2 (LCD), and the 
functional domain of a human defensin protein HD5","Evaluation of LHD 
potency in vivo using mouse model of C. difficile infection (CDI) showed that 
administration of the LHD protein (twice daily for 7 days) was effective in 
mitigating the symptoms and reducing the death from CDI.",,,,
541,30736358.txt,Clostridium difficile infection,hamsters,,,"anti-C. difficile 
whey protein isolates (anti-CD-WPI)","Vancomycin suppressed the growth of 
C. difficile and thus protected the hamsters at the time of administration, but 
90% of these hamsters nevertheless died shortly after discontinuation of 
treatment.",,,,
542,30736358.txt,Clostridium difficile infection,hamsters,,,"anti-C. difficile 
whey protein isolates (anti-CD-WPI)","Oral administration of anti-CD-WPI 
is a functional therapy of CDI in infected hamsters for both primary treatment 
and prevention of recurrence.",,,,
543,30736358.txt,Clostridium difficile infection,hamsters,,,Vancomycin,"Vancomycin suppressed the growth of 
C. difficile and thus protected the hamsters at the time of administration, but 
90% of these hamsters nevertheless died shortly after discontinuation of 
treatment.",,,,
544,30736358.txt,Clostridium difficile infection,hamsters,,,Vancomycin,"Oral administration of anti-CD-WPI 
is a functional therapy of CDI in infected hamsters for both primary treatment 
and prevention of recurrence.",,,,
545,30816855.txt,C. difficile,mice,,,"E. coli 
expressing highly active BSH","C. difficile total viable 
counts were ~70% reduced in an rCDI mouse model after administration of E. coli 
expressing highly active BSH relative to mice administered BSH-negative E. coli 
(p<0.05).",,,,
546,30842760.txt,Clostridium difficile,murine,,,L. gasseri APC 678,"It was established that, relative to control mice not fed 
Lactobacillus, feeding with L. gasseri APC 678 resulted in a significant 
reduction by day 7 (8-fold, p = 0.017) of viable C. difficile VPI 10463 in the 
feces of mice.",,VPI 10463,,
547,30842760.txt,Clostridium difficile,murine,,,L. gasseri APC 678,"In contrast, neither L. rhamnosus DPC 6111 nor L. gasseri ATCC 
33323 significantly reduced fecal C. difficile shedding.",,VPI 10463,,
548,30842760.txt,Clostridium difficile,murine,,,L. rhamnosus DPC 6111,"It was established that, relative to control mice not fed 
Lactobacillus, feeding with L. gasseri APC 678 resulted in a significant 
reduction by day 7 (8-fold, p = 0.017) of viable C. difficile VPI 10463 in the 
feces of mice.",,VPI 10463,,
549,30842760.txt,Clostridium difficile,murine,,,L. rhamnosus DPC 6111,"In contrast, neither L. rhamnosus DPC 6111 nor L. gasseri ATCC 
33323 significantly reduced fecal C. difficile shedding.",,VPI 10463,,
550,30842760.txt,Clostridium difficile,murine,,,L. gasseri ATCC 33323,"It was established that, relative to control mice not fed 
Lactobacillus, feeding with L. gasseri APC 678 resulted in a significant 
reduction by day 7 (8-fold, p = 0.017) of viable C. difficile VPI 10463 in the 
feces of mice.",,VPI 10463,,
551,30842760.txt,Clostridium difficile,murine,,,L. gasseri ATCC 33323,"In contrast, neither L. rhamnosus DPC 6111 nor L. gasseri ATCC 
33323 significantly reduced fecal C. difficile shedding.",,VPI 10463,,
552,30901686.txt,Clostridioides (formerly Clostridium) difficile,murine,,,"biaryl peptidomimetics 28 
and 67","The biaryl peptidomimetics 28 
and 67 were found to exhibit significant efficacy in an in vivo murine model of 
C. difficile infection by reducing the severity and slowing the onset of 
disease.",,,,
553,30988143.txt,"Clostridioides 
(Clostridium) difficile infections (CDIs)",mouse,,"cefoperazone over 5 days and subsequently challenged with 102 C. difficile VPI 
10463 spores","108 CFU of probiotics 
daily","Using total clinical scores, we identified an association between probiotic 
treatment and delayed onset of primary CDI and relapse by approximately 12 to 
24 h (P < 0.001).",,,,
554,30995474.txt,Clostridium difficile.,mice,,,Butyrate,"it attenuates intestinal inflammation 
and improves intestinal barrier function in infected mice, as shown by reduced 
intestinal epithelial permeability and bacterial translocation, effects 
associated with the increased expression of components of intestinal epithelial 
cell tight junctions.",,,,
555,31178844.txt,Clostridium difficile (,murine,,,"vancomycin-loaded spore-targeting iron oxide nanoparticle 
(van-IONP)","In a murine model of C. difficile infection, 
the van-IONP significantly protected the mice from infected by C. difficile 
infection, reducing intestinal inflammation, and facilitated superior mucosal 
viability compared with equal doses of free vancomycin.",,,,
556,31233493.txt,Clostridium difficile infection,mice,,,DLD-4,DLD-4 also protected mice from a toxin challenge in vivo.,,,,
557,31406331.txt,C. difficile disease,mouse,,,"combined 
treatment with the current standard-of-care antibiotic, vancomycin, and a 
cephamycin","Using a mouse disease model, we show that combined 
treatment with the current standard-of-care antibiotic, vancomycin, and a 
cephamycin prevents disease recurrence.",,,,
558,31560732.txt,Clostridium difficile (Cd) infection,mice,,,"fecal microbiota 
transplantation","This colonization 
resistance was transferred from MR1-/- to WT mice via fecal microbiota 
transplantation, suggesting that MR1-dependent factors influence the microbiota, 
leading to CDI susceptibility.",,,,
559,31636067.txt,Clostridioides difficile,hamsters,,,DAV131A,"We show here that DAV131A, a charcoal-based adsorbent, 
decreases the intestinal levels of the fluoroquinolone antibiotics levofloxacin 
and ciprofloxacin in hamsters, protects their intestinal microbiota, and 
prevents lethal infection by C. difficile.",,,,
560,31636067.txt,Clostridioides difficile,hamsters,,,levofloxacin,"We show here that DAV131A, a charcoal-based adsorbent, 
decreases the intestinal levels of the fluoroquinolone antibiotics levofloxacin 
and ciprofloxacin in hamsters, protects their intestinal microbiota, and 
prevents lethal infection by C. difficile.",,,,
561,31636067.txt,Clostridioides difficile,hamsters,,,ciprofloxacin,"We show here that DAV131A, a charcoal-based adsorbent, 
decreases the intestinal levels of the fluoroquinolone antibiotics levofloxacin 
and ciprofloxacin in hamsters, protects their intestinal microbiota, and 
prevents lethal infection by C. difficile.",,,,
562,31642901.txt,Clostridioides difficile,Mice,,,auranofin,"Mice treated with auranofin 
lost less weight, displayed a significant increase in survival rates and had 
significantly less toxin-mediated damage in their colon and caecum compared with 
control mice.",,,,
563,31748246.txt,Clostridioides difficile infections,Mice,,,omeprazole,"These results suggest that 
omeprazole treatment alone is not sufficient to disrupt microbiota resistance to 
C. difficile infection in mice that are normally resistant in the absence of 
antibiotic treatment.IMPORTANCE",,,,
564,31793403.txt,C. difficile disease,Mice,,clindamycin,,"Mice given clindamycin 
alone became colonized but displayed no tissue pathology while severe disease, 
exemplified by weight loss and inflammatory tissue damage occurred in animals 
given a combination of five antibiotics and clindamycin.",,,,
565,31793403.txt,C. difficile disease,Mice,,clindamycin,,"Animals given only the 
five antibiotic cocktails showed only transient colonization and no disease.",,,,
566,31793629.txt,Clostridium difficile infection,mice,,,Anti-MIP-1 α neutralizing antibody,"Anti-MIP-1 α neutralizing antibody 
prevented death, ameliorated colonic injury, reduced colonic interleukin 1β 
(IL-1β) messenger RNA expression, and restored colonic SLC26a3 expression",,,,
567,31838076.txt,,mice,,antibiotics,lactotrehalose,"Lactotrehalose 
and trehalose reduced markers of inflammation in rectal tissue after CD027 
infection.",,CD027,,
568,31838076.txt,,mice,,antibiotics,trehalose,"Lactotrehalose 
and trehalose reduced markers of inflammation in rectal tissue after CD027 
infection.",,CD027,,
569,31849218.txt,Clostridium difficile infection,mouse,,,TNP-2092,"In vivo, TNP-2092 demonstrated potent 
efficacy in a mouse Clostridium difficile infection model, superior to 
metronidazole and vancomycin, with no relapse observed after treatment.",,,,
570,31849218.txt,Clostridium difficile infection,mouse,,,metronidazole,"In vivo, TNP-2092 demonstrated potent 
efficacy in a mouse Clostridium difficile infection model, superior to 
metronidazole and vancomycin, with no relapse observed after treatment.",,,,
571,31849218.txt,Clostridium difficile infection,mouse,,,vancomycin,"In vivo, TNP-2092 demonstrated potent 
efficacy in a mouse Clostridium difficile infection model, superior to 
metronidazole and vancomycin, with no relapse observed after treatment.",,,,
572,31876919.txt,"Clostridium 
difficile infections",mouse,,,short-chain fatty acid acetate,"We found that administration of acetate is remarkably beneficial 
in ameliorating disease.",,,,
573,31887433.txt,Clostridium difficile infection,mouse,,,Pediococcus acidilactici SPM138 (SPM138),"In a C. difficile PCR ribotype 027-infected mouse model, the 
concentration of CD toxin in stool samples of SPM138-fed mice was only 37% of 
that reported in C. difficile 027-infected group.",,PCR ribotype 027,,
574,31907198.txt,C. difficile,mice,,,ampicillin-resistant bacteria,"Despite the compositional differences 
in the gut microbiota, the severity of C. difficile infection (CDI) and 
mortality did not differ significantly between mice colonized with different 
ampicillin-resistant bacterial species.",,,,
575,31907988.txt,Clostridioides difficile,mice,,,"pregnenolone 
16α-carbonitrile (PCN)","Lastly, to assess the therapeutic 
potential of targeting the PXR, we activated the PXR with pregnenolone 
16α-carbonitrile (PCN) in wild-type mice, which greatly reduced the severity of 
TcdA/B-induced damage and intestinal inflammation.",,,,
576,31909964.txt,Clostridioides difficile,mouse,,,DHP,"Disruption of TcdB-induced calcium signaling (with both DHP and 
non-DHP molecules) is sufficient to ablate ROS production and prevent subsequent 
necrosis in cells and in a mouse model of intoxication.",,,,
577,31909964.txt,Clostridioides difficile,mouse,,,non-DHP molecules,"Disruption of TcdB-induced calcium signaling (with both DHP and 
non-DHP molecules) is sufficient to ablate ROS production and prevent subsequent 
necrosis in cells and in a mouse model of intoxication.",,,,
578,31915217.txt,Clostridioides difficile,mice,,cefoperazone,Xanthan gum,"As a result, mice that were on the xanthan gum diet experienced limited to 
no C. difficile colonization.",,,,
579,31915217.txt,Clostridioides difficile,mice,,antibiotic cocktail,Xanthan gum,"As a result, mice that were on the xanthan gum diet experienced limited to 
no C. difficile colonization.",,,,
580,31915217.txt,C. difficile,mice,,cefoperazone,Xanthan gum,"As a result, mice that were on the xanthan gum diet experienced limited to 
no C. difficile colonization.",,,,
581,31915217.txt,C. difficile,mice,,antibiotic cocktail,Xanthan gum,"As a result, mice that were on the xanthan gum diet experienced limited to 
no C. difficile colonization.",,,,
582,31921049.txt,Clostridioides difficile infection,mouse,,,"consortium of 
probiotics including five Lactobacilli strains and two Bifidobacterium strains","In summary, the consortium of probiotics effectively 
decreases the colonization of C. difficile, probably via alteration of gut 
microbiota and bile acids.",,NAP1/027,,
583,32047064.txt,C. difficile,mouse,,antibiotic-induced,diets,"In contrast, mice fed a high-carbohydrate diet 
were protected from CDI, despite the high levels of refined carbohydrate and low 
levels of fiber in the diet.",,R20291,,
584,32066975.txt,Clostridioides difficile infection,mice,,,"human 
microbiota-associated","IL-22 signaling in HMA mice regulated host 
glycosylation, which enabled the growth of succinate-consuming bacteria 
Phascolarctobacterium spp. within the gut microbiome.",,,,
585,32084340.txt,Clostridioides difficile,murine,,,Halicin,"Halicin also effectively treated 
Clostridioides difficile and pan-resistant Acinetobacter baumannii infections in 
murine models.",,,,
586,32156803.txt,C. difficile,mouse,,,"recombinant bacteriophage expressing 
bacterial genome-targeting CRISPR RNAs","We demonstrate that a recombinant bacteriophage expressing 
bacterial genome-targeting CRISPR RNAs is significantly more effective than its 
wild-type parent bacteriophage at killing C. difficile both in vitro and in a 
mouse model of CDI.",,,,
587,32156806.txt,Clostridioides difficile,murine,,,amoxapine,"Overall, 
our lead drugs promote disease alleviation and survival in the murine model",,,,
588,32156806.txt,Clostridioides difficile,murine,,,doxapram,"Overall, 
our lead drugs promote disease alleviation and survival in the murine model",,,,
589,32156806.txt,Clostridioides difficile,murine,,,trifluoperazine,"Overall, 
our lead drugs promote disease alleviation and survival in the murine model",,,,
590,32165071.txt,"Clostridioides difficile 
infection.",mouse,,intraperitoneal clindamycin,vancomycin,"Both C. difficile inoculation and treatment with vancomycin or 
fidaxomicin reduced microbiota diversity; however, dysbiosis associated with 
fidaxomicin was milder than with vancomycin.",,BI/NAP1/027,,
591,32165071.txt,"Clostridioides difficile 
infection.",mouse,,intraperitoneal clindamycin,fidaxomicin,"Both C. difficile inoculation and treatment with vancomycin or 
fidaxomicin reduced microbiota diversity; however, dysbiosis associated with 
fidaxomicin was milder than with vancomycin.",,BI/NAP1/027,,
592,32165071.txt,"Clostridioides difficile 
infection.",mouse,,intraperitoneal clindamycin,Clostridium butyricum MIYAIRI 588,"Both C. difficile inoculation and treatment with vancomycin or 
fidaxomicin reduced microbiota diversity; however, dysbiosis associated with 
fidaxomicin was milder than with vancomycin.",,BI/NAP1/027,,
593,32165071.txt,"Clostridioides difficile 
infection.",mouse,,intraperitoneal clindamycin,lactoferrin,"Both C. difficile inoculation and treatment with vancomycin or 
fidaxomicin reduced microbiota diversity; however, dysbiosis associated with 
fidaxomicin was milder than with vancomycin.",,BI/NAP1/027,,
594,32190927.txt,Clostridioides difficile,mice,,intestinal loops,α-defensin-1,"In mice, the application of α-defensin-1 reduced the TcdA-induced damage of 
intestinal loops in vivo.",,,,
595,32205405.txt,Clostridioides difficile infection,murine,,,ursodiol,"Although ursodiol pretreatment did not result in a consistent 
decrease in the C. difficile life cycle in vivo, it was able to attenuate an 
overly robust inflammatory response that is detrimental to the host during CDI.",,R20291,,
596,32351460.txt,Clostridioides difficile,mice,,antibiotics,"Lactobacillus reuteri, LMG P-27481","In addition, LMG P-27481 
supplementation significantly mitigated body weight loss and the extent of 
inflammatory infiltrate and tissue damage.",,,,
597,32382070.txt,Clostridioides difficile,mouse,,,auranofin,"auranofin at low clinically achievable doses (0.125 mg/kg and 
0.25 mg/kg) significantly protected mice against CDI with 100% and 80% survival, 
respectively.",,,,
598,32482070.txt,Clostridioides difficile,mouse,,,salicylanilides,"reduced recurrence of CDI and diminished disturbance of the microbiota 
in mice compared to standard-of-care vancomycin",,,,
599,32482070.txt,Clostridioides difficile,mouse,,,vancomycin,"reduced recurrence of CDI and diminished disturbance of the microbiota 
in mice compared to standard-of-care vancomycin",,,,
600,32483557.txt,Clostridium difficile infection,hamster,,antibiotic-induced,ebselen,"ebselen treatment reduces recurrence 
rates and decreases colitis in a hamster model of relapsing CDI.",,,,
601,32495964.txt,"Clostridioides 
difficile infection",mice,,,probiotic (CD-PRO),"Mice supplemented with targeted spore-forming probiotics exhibited 
improved immune responses and nutrition immunity properties, which were linked 
with less inflammation and enhanced intestinal barrier proteins during recurrent 
CD colonization.",CF-1,,,
602,32495964.txt,"Clostridioides 
difficile infection",mice,,,vancomycin,"Mice supplemented with targeted spore-forming probiotics exhibited 
improved immune responses and nutrition immunity properties, which were linked 
with less inflammation and enhanced intestinal barrier proteins during recurrent 
CD colonization.",CF-1,,,
603,32501140.txt,Clostridioides difficile infection,mice,,,"Fecal 
transplantation with freeze-dried microbiota","Fecal 
transplantation with freeze-dried microbiota allowed engraftment of microbiota 
leading to clearance of Clostridioides difficile infection in a preclinical 
murine model with a survival rate of 70% versus 53-60% in mice treated with 
frozen inocula, and 20% in the untreated group.",,,,
604,32501140.txt,Clostridioides difficile infection,mice,,,frozen inocula,"Fecal 
transplantation with freeze-dried microbiota allowed engraftment of microbiota 
leading to clearance of Clostridioides difficile infection in a preclinical 
murine model with a survival rate of 70% versus 53-60% in mice treated with 
frozen inocula, and 20% in the untreated group.",,,,
605,32635220.txt,,Mice,,,Candida albicans,enhanced survival compared to PBS-fed mice,,,,
606,32635220.txt,,Mice,,,olive oil,enhanced survival compared to PBS-fed mice,,,,
607,32727857.txt,C. difficile,,,,seven simplified communities in a humanized microbiota,"We found that four communities were able to significantly reduce 
the severity of the initial C. difficile infection and limit susceptibility to 
disease relapse.",,,,
608,32775131.txt,"Clostridioides 
difficile infection",mice,,,"activated 
charcoal (AC)","This treatment minimized the 
effect of VCM on gut microbiota and provided protection against Clostridioides 
difficile infection after oral challenge with spores.",,,,
609,32775131.txt,"Clostridioides 
difficile infection",mice,,,vancomycin,"This treatment minimized the 
effect of VCM on gut microbiota and provided protection against Clostridioides 
difficile infection after oral challenge with spores.",,,,
610,32786277.txt,Clostridioides difficile,,,,2-(4-(3-(trifluoromethoxy)phenoxy)picolinamido)benzo[d]oxazole-5-carboxylate,"Animals infected with a lethal dose of 
C. difficile and treated with compound 1 had a similar survival compared to 
treatment with vancomycin, which is the frontline antibiotic used for 
C. difficile infection.",,,,
611,32786277.txt,Clostridioides difficile,,,,vancomycin,"Animals infected with a lethal dose of 
C. difficile and treated with compound 1 had a similar survival compared to 
treatment with vancomycin, which is the frontline antibiotic used for 
C. difficile infection.",,,,
612,32811993.txt,Clostridiodes difficile infection (CDI),mice,,,high-fat diet (HFD)-fed,"Compared to 
control mice, HFD-fed mice failed to clear C. difficile bacteria which resulted 
in protracted diarrhea, weight loss and colonic damage.",,,,
613,32811993.txt,Clostridiodes difficile infection (CDI),mice,,,high-fat diet (HFD)-fed,"Treatment of HFD-fed mice 
with an FXR agonist Obeticholic acid, resulted in decreased primary BA 
synthesis, fewer C. difficile bacteria and better CDI outcomes.",,,,
614,32811993.txt,Clostridiodes difficile infection (CDI),mice,,,Obeticholic acid,"Compared to 
control mice, HFD-fed mice failed to clear C. difficile bacteria which resulted 
in protracted diarrhea, weight loss and colonic damage.",,,,
615,32811993.txt,Clostridiodes difficile infection (CDI),mice,,,Obeticholic acid,"Treatment of HFD-fed mice 
with an FXR agonist Obeticholic acid, resulted in decreased primary BA 
synthesis, fewer C. difficile bacteria and better CDI outcomes.",,,,
616,32811993.txt,C. difficile,mice,,,high-fat diet (HFD)-fed,"Compared to 
control mice, HFD-fed mice failed to clear C. difficile bacteria which resulted 
in protracted diarrhea, weight loss and colonic damage.",,,,
617,32811993.txt,C. difficile,mice,,,high-fat diet (HFD)-fed,"Treatment of HFD-fed mice 
with an FXR agonist Obeticholic acid, resulted in decreased primary BA 
synthesis, fewer C. difficile bacteria and better CDI outcomes.",,,,
618,32811993.txt,C. difficile,mice,,,Obeticholic acid,"Compared to 
control mice, HFD-fed mice failed to clear C. difficile bacteria which resulted 
in protracted diarrhea, weight loss and colonic damage.",,,,
619,32811993.txt,C. difficile,mice,,,Obeticholic acid,"Treatment of HFD-fed mice 
with an FXR agonist Obeticholic acid, resulted in decreased primary BA 
synthesis, fewer C. difficile bacteria and better CDI outcomes.",,,,
620,32841647.txt,Clostridioides difficile,mice,,,TLR9 antagonist,,,,,
621,32954922.txt,C. difficile,mice,,clindamycin,planktonic Lr,,,,,
622,32954922.txt,C. difficile,mice,,clindamycin,Lactobacillus reuteri in its biofilm state,,,,,
623,32960605.txt,Clostridioides difficile,mice,,,HSGN-218,"In addition, HSGN-218 protected mice from CDI recurrence.",,,,
624,33037214.txt,Clostridioides difficile,,,antibiotic-treated,"five-member consortium of 
sialic acid and N-acetylglucosamine utilizers","Using this information, we assembled a five-member consortium of 
sialic acid and N-acetylglucosamine utilizers that impedes C. difficile's access 
to these mucosal sugars and impairs pathogen colonization in antibiotic-treated 
mice.",,,,
625,33045352.txt,Clostridioides difficile infection,mouse,,,ronidazole,"Finally, ronidazole outperformed metronidazole 
when both were tested at a dose of 1 mg/kg daily in a mouse model of CDI.",,,,
626,33045352.txt,Clostridioides difficile infection,mouse,,,metronidazole,"Finally, ronidazole outperformed metronidazole 
when both were tested at a dose of 1 mg/kg daily in a mouse model of CDI.",,,,
627,33072047.txt,Clostridioides difficile infection,hamster,,,OraCAb,"A 
highly significant difference in animal survival for those given an optimized 
OraCAb formulation versus an untreated control group was observed.",,,,
628,33083738.txt,Clostridioides difficile,,,,"LELN-manipulated 
Lactobacillus rhamnosus GG (LGG)","LELN-manipulated 
Lactobacillus rhamnosus GG (LGG) and Streptococcus thermophilus ST-21 (STH) 
(LELN-LS) decrease CDI mortality via an LELN-mediated increase in bile 
resistance and gut survivability.",,,,
629,33083738.txt,Clostridioides difficile,,,,"Streptococcus thermophilus ST-21 (STH) 
(LELN-LS)","LELN-manipulated 
Lactobacillus rhamnosus GG (LGG) and Streptococcus thermophilus ST-21 (STH) 
(LELN-LS) decrease CDI mortality via an LELN-mediated increase in bile 
resistance and gut survivability.",,,,
630,33115949.txt,Clostridioides difficile,mouse,,,"probiotic Saccharomyces 
boulardii to constitutively secrete a single tetra-specific antibody","Here, we engineered probiotic Saccharomyces 
boulardii to constitutively secrete a single tetra-specific antibody that 
potently and broadly neutralized both toxins and demonstrated protection against 
primary and recurrent CDI in both prophylactic and therapeutic mouse models of 
disease.",,,,
631,33202811.txt,Clostridioides difficile,hamster,,,"two uncommon non-toxigenic 
strains (NTCD) belonging to PCR-ribotype (RT) (CE)847 and (CE)032","The survival rate was significantly increased 
when animals received a RT(CE)847 or (CE)032 strain before the 027 strain (4/9 
deaths, p = 0.029; 1/9 death, p = 0.0004, respectively).",,a 027,,
632,33305657.txt,Clostridioides difficile,mouse,,,"C. difficile strain, named NTCD-035","The presence of NTCD-035 in mice prior to challenge with a highly 
pathogenic C. difficile strain (VPI10463) led to significantly reduced disease 
severity.",,VPI10463,,
633,33495229.txt,Clostridioides difficile,hamster,,,OPS-2071,"Furthermore, 
OPS-2071 showed significant in vivo efficacy at 0.0313 mg/kg/day (50% effective 
doses), 39.0-fold and 52.1-fold lower than those of vancomycin and fidaxomicin, 
respectively, in a hamster model of C. difficile infection.",,,,
634,33495229.txt,Clostridioides difficile,hamster,,,vancomycin,"Furthermore, 
OPS-2071 showed significant in vivo efficacy at 0.0313 mg/kg/day (50% effective 
doses), 39.0-fold and 52.1-fold lower than those of vancomycin and fidaxomicin, 
respectively, in a hamster model of C. difficile infection.",,,,
635,33495229.txt,Clostridioides difficile,hamster,,,fidaxomicin,"Furthermore, 
OPS-2071 showed significant in vivo efficacy at 0.0313 mg/kg/day (50% effective 
doses), 39.0-fold and 52.1-fold lower than those of vancomycin and fidaxomicin, 
respectively, in a hamster model of C. difficile infection.",,,,
636,33508620.txt,Clostridioides difficile infection,mouse,,,Bacteroides thetaiotaomicron (B. thetaiotaomicron),"B. thetaiotaomicron administration was associated with a significantly 
increased relative abundance of Bacteroidetes and decreased level of 
Proteobacteria, leading to the reversal of the effect of antibiotics treatment 
and C. difficile infection on microbiota.",,BI/NAP1/027,,
637,33588433.txt,"Clostridioides difficile 
infection","Co-administration of human secretory IgA (sIgA) together with subtherapeutic 
vancomycin significantly enhanced survival in the Clostridioides difficile 
infection (CDI) hamster model .",,,"Co-administration of human secretory IgA (sIgA) together with subtherapeutic 
vancomycin",,,,,
638,33588433.txt,"Clostridioides difficile 
infection",hamster,,,"Co-administration of human secretory IgA (sIgA) together with subtherapeutic 
vancomycin",,,,,
639,33588433.txt,"Clostridioides difficile 
infection","Co-administration of human secretory IgA (sIgA) together with subtherapeutic 
vancomycin significantly enhanced survival in the Clostridioides difficile 
infection (CDI) hamster model .",,,vancomycin,,,,,
640,33588433.txt,"Clostridioides difficile 
infection",hamster,,,vancomycin,,,,,
641,33597149.txt,Clostridioides difficile,mice,,,"Clostridium butyricum 
MIYAIRI588 (CBM588)","We report that CBM588 treatment in mice 
significantly improved clinical symptoms associated with CDI and increased the 
number of neutrophils and Th1 and Th17 cells in the colonic lamina propria in 
the early phase of CDI.",,,,
642,33649048.txt,Clostridioides difficile,mice,,,antibody-mediated blockade of IL-10 signaling,"Similarly, antibody-mediated blockade of IL-10 signaling in wild-type 
C57BL/6 mice conveyed a survival advantage if initiated three weeks prior to 
infection.",C57BL/6,,,
643,3372017.txt,"Clostridium difficile 
infection",mice,,,nontoxinogenic or intermediate clone,"Moreover, these mice were protected 
against further infections with toxinogenic strains of C. difficile, and a 
strong antagonism between nontoxinogenic and toxinogenic clones was observed.",,,,
644,33734244.txt,Clostridium difficile infection,mouse,,,Pediococcus pentosaceus Li05 (Li05),"These results suggest that encapsulating 
Li05 within biopolymer microgels may enhance its ability to prevent and treat 
CDI using functional foods, supplements, or pharmaceuticals.",,,,
645,33734244.txt,Clostridium difficile infection,mouse,,,encapsulated Li05,"These results suggest that encapsulating 
Li05 within biopolymer microgels may enhance its ability to prevent and treat 
CDI using functional foods, supplements, or pharmaceuticals.",,,,
646,33782498.txt,Clostridioides difficile infections,hamster,,,auranofin,"All hamsters treated with auranofin (5 mg/kg) 
survived a lethal challenge with C. difficile.",,,,
647,33782498.txt,Clostridioides difficile infections,hamster,,,auranofin,"Furthermore, auranofin (5 mg/kg) 
was as effective as vancomycin, the drug of choice for treatment of CDIs, 
against relapsing CDI.",,,,
648,33782498.txt,Clostridioides difficile infections,hamster,,,vancomycin,"All hamsters treated with auranofin (5 mg/kg) 
survived a lethal challenge with C. difficile.",,,,
649,33782498.txt,Clostridioides difficile infections,hamster,,,vancomycin,"Furthermore, auranofin (5 mg/kg) 
was as effective as vancomycin, the drug of choice for treatment of CDIs, 
against relapsing CDI.",,,,
650,33785619.txt,Clostridioides difficile,,,,less virulent strain,"Using multiple infection models, we determined that precolonization 
with a less virulent strain is sufficient to protect from challenge with a 
lethal strain of C. difficile, surprisingly even in the absence of adaptive 
immunity.",,,,
651,3815159.txt,Clostridium difficile infection.,mice,,,Saccharomyces boulardii,"Oral preventive treatment of gnotobiotic mice by Saccharomyces boulardii 
significantly decreased mortality following Clostridium difficile infection.",gnotobiotic,,,
652,3909315.txt,,hamster,,,Aztreonam,"In a series of animal-model infections, the drug showed a high degree 
of efficacy that was consistent with findings in studies in vitro.",,,,
653,3909315.txt,,hamster,,,Clostridium difficile-induced,"In a series of animal-model infections, the drug showed a high degree 
of efficacy that was consistent with findings in studies in vitro.",,,,
654,6658814.txt,Clostridium difficile,mice,,,beta-naphthoflavone,"Pretreatment with the microsomal enzyme inducer beta-naphthoflavone 
partially alleviated these effects and increased survival time of intoxicated 
animals.",,,,
655,6673499.txt,Clostridium difficile,mouse,,intestinal loops,chlorpromazine,"Like the fluid secretion induced by cholera toxin, that 
induced by toxin A could be inhibited by chlorpromazine or by depletion of 
intestinal bile.",,,,
656,6673499.txt,Clostridium difficile,mouse,,toxin A,chlorpromazine,"Like the fluid secretion induced by cholera toxin, that 
induced by toxin A could be inhibited by chlorpromazine or by depletion of 
intestinal bile.",,,,
657,6742589.txt,Clostridium difficile,mice,,,cecal content of a healthy young hare,"A microbial barrier effect against challenge-exposure strains of C 
difficile and C perfringens was evidenced in the intestinal tract of recipient 
gnotobiotic mice and young hares.",gnotobiotic,,,
658,7001883.txt,Clostridium difficile,mice,,,human fecal flora,"In 
these mice, nonetheless, the colonizing human fecal flora exerted an effective 
barrier against a toxigenic strain of Clostridium difficile.",,,,
659,7309245.txt,Clostridium difficile,hamsters,,,cecal homogenates,"Administration of normal cecal homogenates decreased numbers of viable 
Clostridium difficile and prevented cecitis in antibiotic-challenged hamsters.",,,,
660,7365273.txt,Clostridium difficile,hamster,,clindamycin-induced cecitis.,Cholestyramine,"Both compounds 
delayed death and reduced levels of cytotoxin in stool; these effects were 
greatest for vancomycin",,,,
661,7365273.txt,Clostridium difficile,hamster,,clindamycin-induced cecitis.,vancomycin,"Both compounds 
delayed death and reduced levels of cytotoxin in stool; these effects were 
greatest for vancomycin",,,,
662,7380566.txt,Clostridium difficile,mice,,,clindamycin,"Treatment of mice with 
concentrations of clindamycin shown to be inhibitory in vitro had no effect on 
C. difficile toxin titers or bacterial counts, although the appearance of a 
clindamycin-resistant population was noted.",Germfree,,,
663,7380566.txt,Clostridium difficile,mice,,,vancomycin,"Treatment of mice with 
concentrations of clindamycin shown to be inhibitory in vitro had no effect on 
C. difficile toxin titers or bacterial counts, although the appearance of a 
clindamycin-resistant population was noted.",Germfree,,,
664,7380566.txt,Clostridium difficile,mice,,,clindamycin,"These data indicate that vancomycin, 
given orally, decreases the concentration of toxin, but C. difficile survive as 
spores.",Germfree,,,
665,7380566.txt,Clostridium difficile,mice,,,vancomycin,"These data indicate that vancomycin, 
given orally, decreases the concentration of toxin, but C. difficile survive as 
spores.",Germfree,,,
666,7399686.txt,Clostridium difficile,mice,,,antitoxin,"Antitoxin dilutions of 1/8,000 and 1/5,120 were capable of 
neutralizing lethal doses of the toxin in mice and in tissue culture, 
respectively.",,,,
667,7508124.txt,Clostridium difficile,rats,,ileal loops,"CP-96,345","Pretreatment of rats with CP-96,345 (2.5 mg per kg of body 
weight), a substance P antagonist, dramatically inhibited fluid secretion (P < 
0.01) and mannitol permeability (P < 0.01) in ileal loops exposed to toxin A",,,,
668,759263.txt,Clostridium difficile,,,clindamycin,C. sordellii antitoxin,"Administration of 300 U of 
antitoxin parenterally either on the day of challenge with clindamycin or 24 hr 
later provided significant protection (25% mortality vs. 100% mortality in 
controls, P less than 0.01).",,,,
669,759263.txt,Clostridium difficile,,,clindamycin,C. sordellii antitoxin,"None of eight animals given antitoxin (300 U) both 
on the day of challenge and 24 hr later died.",,,,
670,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,vancomycin,"This organism is 
susceptible to vancomycin and metronidazole, and the disease could be prevented 
in the hamster so long as the antibiotics were given orally.",,,,
671,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,metronidazole,"This organism is 
susceptible to vancomycin and metronidazole, and the disease could be prevented 
in the hamster so long as the antibiotics were given orally.",,,,
672,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,cholestyramine,"This organism is 
susceptible to vancomycin and metronidazole, and the disease could be prevented 
in the hamster so long as the antibiotics were given orally.",,,,
673,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,Lomotil,"This organism is 
susceptible to vancomycin and metronidazole, and the disease could be prevented 
in the hamster so long as the antibiotics were given orally.",,,,
674,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,vancomycin,"Administration of 
cholestyramine significantly prolonged survival of hamsters, but did not pervent 
death or colitis.",,,,
675,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,metronidazole,"Administration of 
cholestyramine significantly prolonged survival of hamsters, but did not pervent 
death or colitis.",,,,
676,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,cholestyramine,"Administration of 
cholestyramine significantly prolonged survival of hamsters, but did not pervent 
death or colitis.",,,,
677,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,Lomotil,"Administration of 
cholestyramine significantly prolonged survival of hamsters, but did not pervent 
death or colitis.",,,,
678,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,vancomycin,"Corticosteroids or atropine-diphenoxylate (Lomotil) did not 
alter the disease.",,,,
679,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,metronidazole,"Corticosteroids or atropine-diphenoxylate (Lomotil) did not 
alter the disease.",,,,
680,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,cholestyramine,"Corticosteroids or atropine-diphenoxylate (Lomotil) did not 
alter the disease.",,,,
681,760500.txt,"Clostridium 
difficile",hamster,,clindamycin,Lomotil,"Corticosteroids or atropine-diphenoxylate (Lomotil) did not 
alter the disease.",,,,
682,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,vancomycin,"This organism is 
susceptible to vancomycin and metronidazole, and the disease could be prevented 
in the hamster so long as the antibiotics were given orally.",,,,
683,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,metronidazole,"This organism is 
susceptible to vancomycin and metronidazole, and the disease could be prevented 
in the hamster so long as the antibiotics were given orally.",,,,
684,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,cholestyramine,"This organism is 
susceptible to vancomycin and metronidazole, and the disease could be prevented 
in the hamster so long as the antibiotics were given orally.",,,,
685,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,Lomotil,"This organism is 
susceptible to vancomycin and metronidazole, and the disease could be prevented 
in the hamster so long as the antibiotics were given orally.",,,,
686,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,vancomycin,"Administration of 
cholestyramine significantly prolonged survival of hamsters, but did not pervent 
death or colitis.",,,,
687,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,metronidazole,"Administration of 
cholestyramine significantly prolonged survival of hamsters, but did not pervent 
death or colitis.",,,,
688,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,cholestyramine,"Administration of 
cholestyramine significantly prolonged survival of hamsters, but did not pervent 
death or colitis.",,,,
689,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,Lomotil,"Administration of 
cholestyramine significantly prolonged survival of hamsters, but did not pervent 
death or colitis.",,,,
690,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,vancomycin,"Corticosteroids or atropine-diphenoxylate (Lomotil) did not 
alter the disease.",,,,
691,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,metronidazole,"Corticosteroids or atropine-diphenoxylate (Lomotil) did not 
alter the disease.",,,,
692,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,cholestyramine,"Corticosteroids or atropine-diphenoxylate (Lomotil) did not 
alter the disease.",,,,
693,760500.txt,"Clostridium 
difficile",Corticosteroids,,clindamycin,Lomotil,"Corticosteroids or atropine-diphenoxylate (Lomotil) did not 
alter the disease.",,,,
694,77366.txt,C. difficile,hamsters,,,vancomycin,"Use of the strains from 2 patients induced a fatal 
enterocolitis when inoculated orally into hamsters pretreated with vancomycin.",,,,
695,7909488.txt,Clostridium difficile,rats,,jejunum,indomethacin,"indomethacin but not the 5-hydroxytryptamine receptor antagonists 
ketanserin plus tropisetron were able to inhibit toxin A-induced fluid 
secretion.",,,,
696,7909488.txt,Clostridium difficile,rats,,jejunum,indomethacin,"Atropine and hexamethonium were without effect on the action of toxin 
A, such excluding a nervous mechanism.",,,,
697,7909488.txt,Clostridium difficile,rats,,jejunum,ketanserin,"indomethacin but not the 5-hydroxytryptamine receptor antagonists 
ketanserin plus tropisetron were able to inhibit toxin A-induced fluid 
secretion.",,,,
698,7909488.txt,Clostridium difficile,rats,,jejunum,ketanserin,"Atropine and hexamethonium were without effect on the action of toxin 
A, such excluding a nervous mechanism.",,,,
699,7909488.txt,Clostridium difficile,rats,,jejunum,tropisetron,"indomethacin but not the 5-hydroxytryptamine receptor antagonists 
ketanserin plus tropisetron were able to inhibit toxin A-induced fluid 
secretion.",,,,
700,7909488.txt,Clostridium difficile,rats,,jejunum,tropisetron,"Atropine and hexamethonium were without effect on the action of toxin 
A, such excluding a nervous mechanism.",,,,
701,7909488.txt,Clostridium difficile,rats,,jejunum,Atropine,"indomethacin but not the 5-hydroxytryptamine receptor antagonists 
ketanserin plus tropisetron were able to inhibit toxin A-induced fluid 
secretion.",,,,
702,7909488.txt,Clostridium difficile,rats,,jejunum,Atropine,"Atropine and hexamethonium were without effect on the action of toxin 
A, such excluding a nervous mechanism.",,,,
703,7909488.txt,Clostridium difficile,rats,,jejunum,hexamethonium,"indomethacin but not the 5-hydroxytryptamine receptor antagonists 
ketanserin plus tropisetron were able to inhibit toxin A-induced fluid 
secretion.",,,,
704,7909488.txt,Clostridium difficile,rats,,jejunum,hexamethonium,"Atropine and hexamethonium were without effect on the action of toxin 
A, such excluding a nervous mechanism.",,,,
705,7915699.txt,Clostridium difficile,rat,,toxin A,lidocaine,"Lidocaine, hexamethonium, and capsaicin, but not atropine, inhibited 
toxin A-mediated secretion and MPO activity, but only capsaicin reduced mannitol 
permeability.",,,,
706,7915699.txt,Clostridium difficile,rat,,ileum,lidocaine,"Lidocaine, hexamethonium, and capsaicin, but not atropine, inhibited 
toxin A-mediated secretion and MPO activity, but only capsaicin reduced mannitol 
permeability.",,,,
707,7915699.txt,Clostridium difficile,rat,,toxin A,hexamethonium,"Lidocaine, hexamethonium, and capsaicin, but not atropine, inhibited 
toxin A-mediated secretion and MPO activity, but only capsaicin reduced mannitol 
permeability.",,,,
708,7915699.txt,Clostridium difficile,rat,,ileum,hexamethonium,"Lidocaine, hexamethonium, and capsaicin, but not atropine, inhibited 
toxin A-mediated secretion and MPO activity, but only capsaicin reduced mannitol 
permeability.",,,,
709,7915699.txt,Clostridium difficile,rat,,toxin A,atropine,"Lidocaine, hexamethonium, and capsaicin, but not atropine, inhibited 
toxin A-mediated secretion and MPO activity, but only capsaicin reduced mannitol 
permeability.",,,,
710,7915699.txt,Clostridium difficile,rat,,ileum,atropine,"Lidocaine, hexamethonium, and capsaicin, but not atropine, inhibited 
toxin A-mediated secretion and MPO activity, but only capsaicin reduced mannitol 
permeability.",,,,
711,7915699.txt,Clostridium difficile,rat,,toxin A,capsaicin,"Lidocaine, hexamethonium, and capsaicin, but not atropine, inhibited 
toxin A-mediated secretion and MPO activity, but only capsaicin reduced mannitol 
permeability.",,,,
712,7915699.txt,Clostridium difficile,rat,,ileum,capsaicin,"Lidocaine, hexamethonium, and capsaicin, but not atropine, inhibited 
toxin A-mediated secretion and MPO activity, but only capsaicin reduced mannitol 
permeability.",,,,
713,8395445.txt,Clostridium difficile,rat,,"toxin 
A-induced enterotoxicity in rat ileum.",ketotifen,"Ketotifen pretreatment inhibited toxin A-associated intestinal 
secretion by 42.5% and mannitol permeability by 56.3% and reduced epithelial 
cell inflammation and necrosis.",,,,
714,8429534.txt,C. difficile,hamsters,,clindamycin,caecal contents,"Small amounts of normal caecal contents inhibited the growth of 
C. difficile when added to cultures in vitro or given to animals which had been 
treated with clindamycin.",,,,
715,8429534.txt,C. difficile,hamsters,,ampicillin,caecal contents,"Small amounts of normal caecal contents inhibited the growth of 
C. difficile when added to cultures in vitro or given to animals which had been 
treated with clindamycin.",,,,
716,8462799.txt,,rat,,toxin A,Saccharomyces boulardii,"Treatment of rats with S. boulardii suspension 
reduced fluid secretion and mannitol permeability caused by toxin A.",,,,
717,8462799.txt,,rat,,ileal loops,Saccharomyces boulardii,"Treatment of rats with S. boulardii suspension 
reduced fluid secretion and mannitol permeability caused by toxin A.",,,,
718,8510136.txt,Clostridium difficile,mice,,,serogroup F strains,"these 
mice were protected against subsequent challenge with the otherwise lethally 
toxigenic C. difficile strain VPI 10463.",axenic,VPI 10463,,
719,8690209.txt,Clostridium difficile,rats,,ileal loops,Synsorb 90,"Pretreatment of rats with Synsorb 90 by gavage (200 mg/kg body wt), but no 
Synsorb 83 or Chromosorb P at the same doses, dramatically reduced toxin 
A-associated fluid secretion and permeability.",,,,
720,8690209.txt,Clostridium difficile,rats,,ileal loops,Synsorb 83,"Pretreatment of rats with Synsorb 90 by gavage (200 mg/kg body wt), but no 
Synsorb 83 or Chromosorb P at the same doses, dramatically reduced toxin 
A-associated fluid secretion and permeability.",,,,
721,8690209.txt,Clostridium difficile,rats,,ileal loops,Chromosorb P,"Pretreatment of rats with Synsorb 90 by gavage (200 mg/kg body wt), but no 
Synsorb 83 or Chromosorb P at the same doses, dramatically reduced toxin 
A-associated fluid secretion and permeability.",,,,
722,8698855.txt,Clostridium difficile,rabbit,,ileal loops,anti-SI IgG,"Furthermore, anti-SI IgG inhibited toxin A-induced secretion (by 78.1%, P < 
0.01), intestinal permeability (by 80.8%, P < 0.01), and histologic injury (P < 
0.01) in rabbit ileal loops in vivo.",,,,
723,8834883.txt,Clostridium difficile,rat,,toxin A,Anti-C. difficile bovine immunoglobulin concentrate,"anti-C. difficile bovine immunoglobulin 
concentrate neutralizes the cytotoxic effects of C. difficile toxins in vitro 
and inhibits their enterotoxic effects in vivo.",,,,
724,8834883.txt,Clostridium difficile,rat,,ileal loop,Anti-C. difficile bovine immunoglobulin concentrate,"anti-C. difficile bovine immunoglobulin 
concentrate neutralizes the cytotoxic effects of C. difficile toxins in vitro 
and inhibits their enterotoxic effects in vivo.",,,,
725,8945570.txt,Clostridium difficile,rat,,toxin A,S. boulardii protease,S. boulardii protease inhibits the intestinal effects,,,,
726,8945570.txt,Clostridium difficile,rat,,ileal loops,S. boulardii protease,S. boulardii protease inhibits the intestinal effects,,,,
727,9114070.txt,Clostridium difficile,rats,,,"CP-96,345","Pretreatment of rats with the SP antagonist 
CP-96,345 inhibits toxin A-mediated TNFalpha release from isolated LPMs, whereas 
an inactive enantiomer (CP-96,344) of the SP antagonist has no effect.",,,,
728,9191992.txt,C. difficile,mice,,,20% fermentable fibre,"This 
resulted in elimination of C. difficile from 6/7 C. difficile colonized mice 
within 6 days of beginning a diet containing 20% fermentable fibre.",,,,
729,9199444.txt,Clostridium difficile,rats,,toxin A,BWA4C,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
730,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,BWA4C,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
731,9199444.txt,Clostridium difficile,rats,,toxin A,nordihydroguaiaretic acid,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
732,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,nordihydroguaiaretic acid,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
733,9199444.txt,Clostridium difficile,rats,,toxin A,mepacrine,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
734,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,mepacrine,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
735,9199444.txt,Clostridium difficile,rats,,toxin A,dexamethasone,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
736,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,dexamethasone,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
737,9199444.txt,Clostridium difficile,rats,,toxin A,indomethacin,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
738,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,indomethacin,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
739,9199444.txt,Clostridium difficile,rats,,toxin A,platelet-activating factor antagonist BN52021,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
740,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,platelet-activating factor antagonist BN52021,"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
741,9199444.txt,Clostridium difficile,rats,,toxin A,anti-interleukin-1beta (anti-IL-1beta),"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
742,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,anti-interleukin-1beta (anti-IL-1beta),"Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
743,9199444.txt,Clostridium difficile,rats,,toxin A,"anti-tumor 
necrosis factor alpha (anti-TNF-alpha) antibodies","Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
744,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,"anti-tumor 
necrosis factor alpha (anti-TNF-alpha) antibodies","Pretreatment of rats 
with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the 
neutrophil migration evoked by toxin A in the peritoneal cavities.",,,,
745,9199444.txt,Clostridium difficile,rats,,toxin A,BWA4C,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
746,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,BWA4C,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
747,9199444.txt,Clostridium difficile,rats,,toxin A,nordihydroguaiaretic acid,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
748,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,nordihydroguaiaretic acid,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
749,9199444.txt,Clostridium difficile,rats,,toxin A,mepacrine,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
750,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,mepacrine,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
751,9199444.txt,Clostridium difficile,rats,,toxin A,dexamethasone,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
752,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,dexamethasone,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
753,9199444.txt,Clostridium difficile,rats,,toxin A,indomethacin,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
754,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,indomethacin,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
755,9199444.txt,Clostridium difficile,rats,,toxin A,platelet-activating factor antagonist BN52021,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
756,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,platelet-activating factor antagonist BN52021,"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
757,9199444.txt,Clostridium difficile,rats,,toxin A,anti-interleukin-1beta (anti-IL-1beta),"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
758,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,anti-interleukin-1beta (anti-IL-1beta),"However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
759,9199444.txt,Clostridium difficile,rats,,toxin A,"anti-tumor 
necrosis factor alpha (anti-TNF-alpha) antibodies","However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
760,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,"anti-tumor 
necrosis factor alpha (anti-TNF-alpha) antibodies","However, 
pretreatment with the cyclooxygenase inhibitor indomethacin or the 
platelet-activating factor antagonist BN52021 fails to alter toxin A-induced 
neutrophil migration.",,,,
761,9199444.txt,Clostridium difficile,rats,,toxin A,BWA4C,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
762,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,BWA4C,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
763,9199444.txt,Clostridium difficile,rats,,toxin A,nordihydroguaiaretic acid,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
764,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,nordihydroguaiaretic acid,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
765,9199444.txt,Clostridium difficile,rats,,toxin A,mepacrine,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
766,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,mepacrine,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
767,9199444.txt,Clostridium difficile,rats,,toxin A,dexamethasone,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
768,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,dexamethasone,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
769,9199444.txt,Clostridium difficile,rats,,toxin A,indomethacin,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
770,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,indomethacin,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
771,9199444.txt,Clostridium difficile,rats,,toxin A,platelet-activating factor antagonist BN52021,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
772,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,platelet-activating factor antagonist BN52021,"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
773,9199444.txt,Clostridium difficile,rats,,toxin A,anti-interleukin-1beta (anti-IL-1beta),"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
774,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,anti-interleukin-1beta (anti-IL-1beta),"Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
775,9199444.txt,Clostridium difficile,rats,,toxin A,"anti-tumor 
necrosis factor alpha (anti-TNF-alpha) antibodies","Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
776,9199444.txt,Clostridium difficile,rats,,Toxin A was also injected into air pouches,"anti-tumor 
necrosis factor alpha (anti-TNF-alpha) antibodies","Anti-TNF-alpha or 
anti-IL-1beta antibodies significantly reduce the neutrophil migration induced 
by toxin A.",,,,
777,9227329.txt,Clostridium difficile,rats,,Cd Toxin B,MK886 (a lipoxygenase inhibitor),"Pretreating the animals with 
MK886 (a lipoxygenase inhibitor), NDGA (a dual cyclo- and lipoxygenase 
inhibitor) or the glucocorticoid, dexamethasone, but not with indomethacin (a 
cyclo-oxygenase inhibitor), or BN52021 (a platelet-activating factor 
antagonist), inhibited the neutrophil migration evoked by TxB",,,,
778,9227329.txt,Clostridium difficile,rats,,Cd Toxin B,"NDGA (a dual cyclo- and lipoxygenase 
inhibitor)","Pretreating the animals with 
MK886 (a lipoxygenase inhibitor), NDGA (a dual cyclo- and lipoxygenase 
inhibitor) or the glucocorticoid, dexamethasone, but not with indomethacin (a 
cyclo-oxygenase inhibitor), or BN52021 (a platelet-activating factor 
antagonist), inhibited the neutrophil migration evoked by TxB",,,,
779,9227329.txt,Clostridium difficile,rats,,Cd Toxin B,dexamethasone,"Pretreating the animals with 
MK886 (a lipoxygenase inhibitor), NDGA (a dual cyclo- and lipoxygenase 
inhibitor) or the glucocorticoid, dexamethasone, but not with indomethacin (a 
cyclo-oxygenase inhibitor), or BN52021 (a platelet-activating factor 
antagonist), inhibited the neutrophil migration evoked by TxB",,,,
780,9227329.txt,Clostridium difficile,rats,,Cd Toxin B,indomethacin,"Pretreating the animals with 
MK886 (a lipoxygenase inhibitor), NDGA (a dual cyclo- and lipoxygenase 
inhibitor) or the glucocorticoid, dexamethasone, but not with indomethacin (a 
cyclo-oxygenase inhibitor), or BN52021 (a platelet-activating factor 
antagonist), inhibited the neutrophil migration evoked by TxB",,,,
781,9227329.txt,Clostridium difficile,rats,,Cd Toxin B,BN52021,"Pretreating the animals with 
MK886 (a lipoxygenase inhibitor), NDGA (a dual cyclo- and lipoxygenase 
inhibitor) or the glucocorticoid, dexamethasone, but not with indomethacin (a 
cyclo-oxygenase inhibitor), or BN52021 (a platelet-activating factor 
antagonist), inhibited the neutrophil migration evoked by TxB",,,,
782,9277411.txt,Clostridium difficile,rats,,toxin A,recombinant human IL-11 (rhIL-11),"We conclude that 
rhIL-11 blocks the intestinal effects of C. difficile toxin A, possibly by 
inhibiting release of inflammatory mediators from mucosal mast cells and 
intestinal macrophages.",,,,
783,9345763.txt,Clostridium difficile,Mice,,toxin A,recombinant protein (REP231),"Mice immunised with REP231 were protected against 
a threefold lethal dose of TcdA.",,,,
784,9414971.txt,Clostridium difficile,rat,,toxin A,Antisecretory factor (AF),"AF might be involved in protection against 
inflammation and in counteracting dehydration caused by enterotoxins.",,,,
785,9421310.txt,Clostridium difficile,mice,,ampicillin,"AM-1155, a 6-fluoro-8-methoxy quinolone",clinical efficacy of AM-1155 against infections,,,,
786,9558284.txt,Clostridium difficile,mice,,,"P-receptor antagonist 
(CP-96,345)","Administration of a specific substance P-receptor antagonist 
(CP-96,345) reduced toxin A-induced intestinal fluid secretion and inhibited 
neutrophil infiltration in normal, mast cell-deficient KitW/KitW-v, and mast 
cell-reconstituted KitW/KitW-v mice.",,,,
787,9573084.txt,Clostridium difficile,hamsters,,toxin neutralization assay,"avian antibodies against recombinant epitopes of toxin A and toxin 
B","In contrast to vancomycin, CDAD antitoxin prevented 
relapse and subsequent C. difficile reinfection in the hamsters.",Syrian,,,
788,9573084.txt,relapse rates,hamsters,,toxin neutralization assay,"avian antibodies against recombinant epitopes of toxin A and toxin 
B","In contrast to vancomycin, CDAD antitoxin prevented 
relapse and subsequent C. difficile reinfection in the hamsters.",Syrian,,,
789,9753273.txt,,rats,,toxin A,Saccharomyces boulardii,"We conclude 
that rat ceca can be colonized by either organism and that both organisms reduce 
C.diff toxin A-mediated secretion",Sprague-Dawley,,,
790,9753273.txt,,rats,,toxin A,Saccharomyces cerevisiae,"We conclude 
that rat ceca can be colonized by either organism and that both organisms reduce 
C.diff toxin A-mediated secretion",Sprague-Dawley,,,
791,9839563.txt,"Clostridium 
difficile infection.",hamster,,,lactobacilli,"The combination of lactobacilli and xylitol 
had some protective effect against C. difficile infection in these models.",,,,
792,9839563.txt,"Clostridium 
difficile infection.",hamster,,,xylitol,"The combination of lactobacilli and xylitol 
had some protective effect against C. difficile infection in these models.",,,,
